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Calcific aortic valve disease (CAVD) is the most common cause of aortic valve
failure and replacement in the elderly population, affecting 25% of the population over 65
years of age. Current pharmacological approaches for preventing the onset and
progression of calcific aortic valve disease have not shown consistent benefits in clinical
studies. Differentiation of valvular interstitial cells (VICs) into osteoblast–like cells is an
integral step in the calcification process. Although clinical evidence suggests
hypertension as a potential candidate contributing to the development of CAVD, the
underlying molecular mechanisms that cause de-differentiation remain unclear. The
present study investigates the role of elevated cyclic pressure in modulating osteoblast
differentiation pathways in VICs in vitro.
We used a combination of systems biology modeling and pathway-based analyses
to identify novel genes and molecular mechanisms that are activated in valve tissue
during exposure to elevated pressure conditions. Our results show that elevated pressure
induces a gene expression pattern in valve tissue that is considerably similar to that seen

in CAVD, underlining the key role of hypertension as an initiating factor in the onset of
pathogenesis. In addition, our analysis revealed a set of genes that was not previously
known to be regulated in valve tissue in a pressure dependent manner. Currently, the
molecular mechanisms involved in CAVD and their associations with changes in local
mechanical environment are poorly understood, and thus a better understanding of the
cell based process mediating CAVD progression will improve our ability to develop
potential medical therapies for this disease.
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CHAPTER 1
INTRODUCTION AND REVIEW OF LITERATURE
1.1

Aortic Heart Valve Structure and Function
The heart is a three-dimensional hollow, cone-shaped muscle that is responsible

to drive blood from the low-pressure venous system to the high – pressure arterial side of
the circulation. The heart is anatomically divided in four chambers: the right atrium (RA),
right ventricle (RV), left atrium (LA), and left ventricle (LV) 1, 2. Efficient blood pumping
occurs because the organized sequence contraction of the chambers and the presence of
heart valves that ensure unidirectional blood flow through the circulatory system 3.
Cardiac valves are structures that are designed to work like one-way doors. When each
chamber contracts, the valve at its exit opens, and when the contraction is finished, the
valve closes so that blood does not flow backwards 4. Normally, there are four valves
within the heart: the tricuspid valve located between the right atrium and the right
ventricle, the pulmonary valve between the right ventricle and the pulmonary artery, the
mitral valve between the left atrium and the left ventricle and the aortic valve between the
left ventricle and the aorta 5.
The aortic valve (AV), located on the left-hand side of the heart, ensures
unidirectional blood flow from the left ventricle to the ascending aorta without
obstruction or regurgitation during ventricular contraction (systole) and prevents
backflow during ventricular relaxation (diastole) and filling
1

1, 6, 7

(Figure 1). Of the four

valves, the AV is the most frequently associated with disease and surgery 8. The aortic
valve is functionally and mechanically very different from other cardiovascular structures
(e.g. blood vessels, myocardium), and its unique structural conformation is designed to
provide a high degree of flexibility during systole, but also a high degree of strength to
resist the diastolic pressure load 9.

Figure 1.1 Aortic valve location in the heart 3.

The normal aortic valve is composed by three semilunar-shaped leaflets. The
curved edge of the leaflet is attached to the aortic wall while the straight edge is free 2.
The aortic wall bounded by the attachments of the curved edge forms a saccular dilation
called the sinus of Valsalva 2, 4, 7, 10. Each leaflet and corresponding sinus of Valsalva are
named according to their anatomical position to the coronary arteries, thus, they are
known as left coronary (LC) and right coronary (RC) leaflets

7, 10

. The remaining leaflet

is not associated with any coronary artery and is subsequently recalled noncoronary (NC)
leaflet (Figure1.2 A)

7, 10

. The right coronary leaflet has generally a larger size in
2

comparison to the left one and the non-coronary leaflets. In addition, the three leaflets are
completely separated at the free edges by commissures (Figure 1.2 B). The commissures
are named relative to the leaflet on either side, thus, the intercoronary commissure is
located between the left and right coronary leaflets; the left-noncoronary commissure is
located between the left and the noncoronary; and the right-noncoronary commissure is
located between the right and the noncoronary leaflets 2.

Figure 1.2 Anatomical characteristics of aortic valve leaflets. A. Localization of
leaflets in the aortic valve. B. Schematic representation of a valve
leaflet showing the location of the comissures, free edge and
connection to the aortic wall.

Structural integrity of the leaflets is vital for proper valve function as they carry
most of the mechanical stress during the cardiac cycle

5, 11

. Each leaflet is a trilaminar

structure with an approximate thickness of 0.605 ± 0.196 mm 1. Each layer has a specific
arrangement of cells (fibroblasts, mesenchymal cells, endothelial cells) and a
3

polysaccharide-rich extracellular matrix (collagen, elastin, GAGs) (Figure1.3)

12

. It has

been demonstrated that these layers work in concert to provide tensile strength and
pliability to the aortic valve, as there are approximately 40 million openings and closures
of the valve per year (equivalent to approximately 3.7 billion cycles in a single lifetime)9.

Figure 1.3 Aortic valve leaflet structure. Photomicrograph showing immunohistochemical staining of an aortic valve leaflet emphasizing
localization of three major layers (ventricularis, spongiosa, and
fibrosa), and cellular types (endothelial and interstitial cells). Adapted
from Schoen et al 1.

In addition, the composition and structural organization of each layer are major
determinants of valvular mechanical function 12. Facing the left ventricle is the
ventricularis layer; it constitutes about 29% of the overall leaflet thickness and forms the
inflow surface of the valve. It is composed of elastin fibers that are aligned in a radial
direction, perpendicular to the leaflet free margin (Figure 1.4 A) 5, 12, 13. Located
immediately below the aorta is the fibrosa layer; it constitutes 41% of the overall leaflet
4

thickness and forms the outflow surface of the valve. It is primarily composed of
interstitial cells and a dense network of collagen fibers 13, 14. These circumferentiallyoriented packed collagen fibers run parallel to the free edge of the leaflets and they form
the macroscopical folds seen in the aortic surface of each leaflet 11, 12. Both the
ventricularis and the fibrosa are covered by a thin layer of endothelial cells. Finally, the
spongiosa, between the fibrosa and ventricularis, constitutes the larger portion of the
overall leaflet thickness and it is composed of fibroblasts, mesenchymal cells, a disperse
proteoglycans and glycosoaminoglycans (GAGs)- rich matrix and water (Figure 1.4 B)
15, 16.

Figure 1.4 Schematic representation of the aortic valve leaflet. A. Cross
sectional view of the leaflet showing localization of each layer
relative to the aorta. B. Leaflet trilaminar configuration illustrating
the elastin sheets within the ventricularis, GAG-rich matrix
comprising the spongiosa, and the collagen fibers contained within
the fibrosa. A. B modified from Vesely et al 15

The functional consequence of this organization is that each layer displays
differential mechanical properties that contribute to dynamic movement of the valve
during the cardiac cycle

12, 13

. Hence, the fibrosa, rich in collagen fibers, provides
5

resistance to the tensile forces experienced by the leaflets during valve closing (diastole);
the ventricularis, rich in elastin fibers, allows stretching of the leaflet during valve
opening (systole) and the spongiosa provides a cushioning, shear absorption function, and
enables local movement and shearing between the fibrosa and ventricularis layers during
dynamic load 11, 12
1.2

Aortic Heart Valve Cell Phenotypes
The normal aortic valve leaflet is populated with two main cellular phenotypes:

(1) valve endothelial cells (VECs) and (2) valve interstitial cells (VICs) 9. Both cell types
reside within the valve extracellular matrix (ECM) composed by collagen, elastin, and
GAGs 17. VICs are embedded within the extracellular matrix (ECM) of the leaflet while
VECs line the surfaces of each leaflet. Importantly, there is a three way communication
system between VECs/VICs and EMC, in which ECM structure depends on biosynthetic
activity of VECs/VICs, and valve cell phenotype is influenced by the mechanical
properties of the ECM

18, 19

. The interactions between valve cells and ECM are major

determinants of normal aortic valve structure. Thus, abnormal mechanical and
biochemical stimuli on valve leaflets precipitate a series of biological changes in the cells
and in the ECM around cells, which in turn results in alterations in the mechanical
behavior of the valve

1, 5, 20

. In addition, it has been proved that communication between

VICs and VECs plays an important role in valve ECM homeostasis 21.
1.2.1

Valve endothelial cells (VECs)
Valvular endothelial cells line the outer layers of the leaflet. They provide a

smooth and non thrombogenic blood interface on the ventricular and aortic side of each
6

of the valve leaflets17,

22

. Additionally, VECs regulate immune and inflammatory

reactions in the valve; and regulate valve interstitial cell phenotype 9. It has been shown
that VECs are phenotypically different from endothelial cells located in other sites of the
in the vascular system, they have unique characteristics that include: (1) specific pattern
of aligning, as VECs align perpendicular to the direction of blood flow

19, 23

, (2)

proliferative activity, VECs under shear are more proliferative that their aortic
counterparts

21

, (3) specific genetic profiles, VECs located on aortic side of the valve

over express genes that promote valve calcification (i.e. BMP4), this is coupled with
under expression of genes that act as inhibitors of calcification (i.e OPG) 24. Additionally,
VECs from the aortic side appear to express low levels of pro inflammatory genes and
antioxidative enzymes, underlining the protective role of valve endothelium in against
ROS- and inflammatory mechanisms 21, 25.
VECs are directly exposed to shear stress, and thus, they are high responsive to
the local shear changes. Alterations in stretch or shear stress correlate with pathological
activation of VECs and valvular endothelial dysfunction that triggers a series of clinical
events, including inflammatory reactions, release of vasoactive agonists, calcification,
and blood clots

21

. In addition, activated VECs play a key role in proinflammatory

mechanisms; by increasing the expression pro inflammatory proteins such as ICAM-1,
VCAM-, and E-selectin VECs facilitate inflammatory cell recruitment and accumulation
within the valve

9, 25

. Extensive infiltration of inflammatory cells is associated with

altered EM synthesis and calcification in valve tissue; hence alterations in the
biosynthetic activity of VECs may lead to structural alteration and dysfunction of the
valve. Another critical role of VECs in valve homeostasis is the regulation of valvular
7

interstitial cell phenotype. In vitro studies have shown that VECs influences the valvular
interstitial cell phenotype by modulating the expression of α smooth muscle actin
(SMA)19. In addition, it has been show that VICs proliferation is also influence by
communication with VECs.
1.2.2

Valve interstitial cells (VICs)
Valvular interstitial cells (VICs) are the major cellular components of the aortic

valve

26

. They are distributed through all layers of the leaflet and play a key role in

regulating valve tissue homeostasis in normal and pathological conditions. Several
studies have demonstrated the multiple and diverse roles that VICs have in maintaining
normal valve functions

18

. One of the main roles of VICs is regulation of ECM

remodeling. VICs maintain optimal valve function through continual synthesis and repair
of structural components of the ECM (collagen, elastin, GAGs)

27-29

. Furthermore, VICs

are able to regulate and remodel the ECM through expression of matrix
metalloproteinases MMPs and their inhibitors TIMPs
synthesis and degradation of collagen and elastin

31

30

. These proteins are involved in

. Experimental evidence shows that

alterations in the native environment of VICs results in increased ECM degradation and
remodeling that leads dysregulation of normal valve architecture 32.
A major feature of VICs is their extraordinary capacity to modulate their
biosynthetic activity and phenotype in response to the local biomechanical environment
experienced by the valve

9, 33, 34

. In vitro studies show that VICs in the normal valve are

quiescent but in response to mechanical and biochemical stimuli they activate and
differentiate into diverse phenotypes associated with remodeling and repair mechanisms.
Therefore, five different phenotypes have been described:
8

(1)

Embryonic progenitor mesenchymal cells (eVICs): this cell subset is

mainly present during valve development. They are involved in the process that initiates
valve formation in the embryo. Cellular migration and proliferation of eVICs give rise to
quiescent VICs (q VICs) 32.
(2)

Quiescent VICs (qVICs): this cell subset is mainly present in the normal

adult valve. They are thought to maintain physiological valve structure and function
through synthesis and release of ECM remodeling proteins. qVICs display a fibroblastlike phenotype, characterized by the presence of vimentin (intermediate filaments), and
very low levels of α-SMA, MMP-13 (proteolytic enzymes), and SMemb (non-muscle
myosin heavy chain) 29, 35.However, transition of qVICs to an activated phenotype results
in response mechanical and biochemical signals. This phenotypic transition is often
associated with valve injury response and/ or abnormal mechanical conditions 36.
(3)

Activated VICs (aVICs): this cell subset is regularly associated with

pathological conditions in aortic valve. aVICs express high levels of α- smooth muscle
actin, and other contractile proteins

18

. They are believe to activate cellular repair

processes including proliferation, migration, and abnormal extracellular matrix
remodeling through increased expression of a variety of catabolic enzymes, membrane
proteins and growth factors, and cytokines

37, 38

. aVICs have a unique proliferative and

differentiation potential, and it is believed in response to specific biochemical signals (i.e.
TGF-β, BMP2) they trans differentiate into osteoblast-like cells 39, 40.
(4)

Osteoblastic VICs (obVICs); this cell subset is frequently found in

calcified valves41,

42

. They regulate osteogenic and calcification mechanisms in heart

valve. obVICs characterize by the expression of multiple bone-related molecules
9

including alkaline phosphatase (ALP), Runx2, type I collagen (Col I) and osteocalcin
(OC) and the formation of mineralized bone-like structures43,

44

. During osteoblast

differentiation these molecules are expressed at different phases and reflect different
aspects of osteoblast function and bone formation 45.
(5)

Progenitor VICs (pVICs): also referred as valvular stem cells is the valvular cell

type least well defined in the aortic valve. They consist of a heterogeneous population of
progenitor cells that derive from bone marrow cells, circulating cells, and resident
valvular progenitors cells 46. They characterize by the expression of stem cell markers
such as CD34, CD133. In addition, they have a high proliferative potential and the ability
to form blood vessels32. At present there is very limited knowledge of the role of this cell
type in aortic valve homeostasis, but it is believed that they may be important in valve
repair mechanisms.
VICs are strongly attached to the surrounding ECM via diverse of cell-surface,
cytoskeletal and a muscle protein, this fact enables them to sense and response to the
biochemical and mechanical signals experienced by the valve

27

. Therefore, any

substantial change in the native environment of the valve can result in abnormal cellular
phenotypes, secretion of diverse growth factors, cytokines, chemokines and matrix
remodeling enzymes (MMPs, TIMPs), which can compromise the durability and stability
of the valve 31, 47, 48.
1.3

Aortic Heart Valve Biomechanics
The dynamic movement the aortic valve is driven by the highly dynamic and

complex mechanical forces generated by the higher transvalvular pressure gradients
present on the left side of the heart

49

. This includes radial pressure, shear stress that
10

accompanies blood flow, and hoop stress associated with the cardiac cycle

1, 2

. It is

estimated that the normal aortic valve opens and closes more than 3 billion times during
average lifetime 5. Opening and closing of the valve involves changes in the shape,
dimensions, and stress in the structural components of the leaflets (i.e. collagen
realignment and crimping, elastin stretching and shortening) 12, 13, 50.
During systole, the pressure gradient across the valve is basically zero, as the left
ventricle contracts and pumps the blood, the aortic valve opens widely and blood flows
freely from the left ventricle to the aorta 1, 5. During this time, as the valve opens, each
leaflet bends towards the aortic wall. To allow efficient valve opening elastin fibers in the
ventricularis layer recoil decreasing the surface area of each leaflet 16. In addition, during
systole, two different patterns of flow are generated in each side of the leaflet, thus, the
ventricularis layer is exposed to laminar shear stress, and the fibrosa layer is exposed to a
disturbed, oscillatory shear stress13.
During diastole, the normal pressure gradient across the valve is approximately
80mmHg. As the valve closes, and as a result of the increasing pressure, valve leaflets
experience compressive strain and biaxial planar stretch 13. Thus, in order to withstand
the increasing pressure, the collagen fibers in the fibrosa layer unfold, taut and align with
each other. At the end of diastole the leaflets are perfectly aligned preventing blood from
flowing backward to the left ventricle from the aorta. Aortic valve is constructed with a
special strong, yet pliable, fibrous tissue that can withstand the regimens experienced in
every cardiac cycle. Hence, in order to respond to the mechanical demands during systole
(flexion) and diastole (tension) the aortic and ventricular sides of valve leaflets exhibit
drastically different mechanical properties, underlining the anisotropic behavior of valve
11

tissue

12, 13

. Indeed, it has been demonstrated that each layer makes a mechanical

contribution during each phase of the cardiac cycle. During systole, the leaflet response
to mechanical flexure is mainly transmitted by radially-oriented elastin fiber network in
the ventricularis15, 51, whereas in diastole the leaflet response to mechanical tension is
mainly transmited by the circumferentially oriented collagen fibers in the fibrosa layer
(Figure 1.5)12, 52, 53.
Cyclic pressure is one of the most important mechanical forces to which the aortic
valve is exposed during the cardiac cycle. Normally, the pressure gradient across the
aortic valve is approximately 80mmHg; however, the pressure gradient can increase and
become quite high during hypertension (>100 mmHg). Any major increase in the
diastolic pressure gradient across the valve leads to changes in valve leaflet perimeter,
thus imposing larger stresses within the leaflets 9.

12

Figure 1.5

Aortic valve dynamics in the cardiac cycle. A. Mechanical behavior
of elastin and collagen fibers during valve motion. B. Schematic
representation of architecture and configuration of collagen and
elastin in systole and diastole. Modified from Schoen et al 1.

In an important study by Thubrikar et al

14

, the effects of transvalvular pressure

on aortic valve length were measured (Figure 1.6). In addition, they developed a model of
the in vivo leaflet stresses as a function of the transvalvular pressure and considering
bending and stretching as independent components, thus:
(1-1)
P is the transvalvular pressure, R is the radius of the leaflet, T is the thickness, E
is the tissue modulus of elasticity, and the bending stresses are either tensile (+) or
compressive (-) depending on the side of the leaflet 14.

13

Furthermore, several studies have evaluated the effects of elevated pressure by
measuring three types of mechanical loads known to be involved in cardiac cycle namely
stretch, shear and pressure.First, non physiological mechanical stretch has been known to
stimulate cell proliferation, apoptosis and capthesin expression

54

. In addition, non

physiological stretch induces increase in collagen content and alteration in valve
mechanical properties. Secondly, cyclic pressure is involved in altered DNA and collagen
synthesis, increased cellular stiffness and altered collagen arrangement in valve tissue
55, 56

50,

.Some studies have suggested that altered shear stress regimens result in endothelial

injury and activation of pro inflammatory mechanisms in the valve.
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Figure 1.6 Typical plot of leaflet length vs. pressure gradient across the leaflet in
vivo in a single dog. The circles represent measured leaflet length and
measured pressure gradient in diastole. The bars represent measured
leaflet length and assumed pressure gradient of 0 to 10mmHg in
systole. The lengths ℓ0, ℓ, ℓ1, and ℓ2 correspond to the gradients of 0,
10, 60, and 200mmHg, respectively. Diastolic strain is represented by
εD, whereas systolic strain is represented by εS 14.

Several experimental models have revealed the drastic changes that occur in valve
structure during each cardiac cycle5, 7. Moreover, it has been shown that the long-term
consequences of extreme and continual loading conditions may include alterations in
valve cell phenotype, abnormal ECM architecture, valve degeneration and failure

57

.

These studies underline the significant role of mechanical loads in regulating the
mechanical and biological behavior of the aortic valve.

15

1.4

Aortic Heart Valve Calcification
Calcific aortic valve disease (CAVD) is the most common disease of the aortic

valve. Epidemiological studies of different populations have shown that CAVD is present
in 28% of adults with a mean age of 50 years 58. Similar results have been found in
previous population-based studies, where the prevalence of the disease is between 21%26% in adults aged 55–71 years 59, 60. It is estimated that CAVD is the most prevalent
valvular disease in western population and the main cause of heart valve replacement in
the elderly, with about 40,000 valve operations in Europe and 95,000 in the United States
done per year 8.
Increased leaflet stiffness and thickness, reduction in the orifice area, and
incomplete opening of the valve are the main characteristics of calcified human valves 6163

. When calcification and thickening are severe, the increased stiffness of the valve

leaflets results in an obstruction at the valvular level. Presumably, valvular narrowing
associated with obstruction due to restricted opening of valve leaflets generates turbulent
flow in the region of the sinus of Valsalva 9. Increased Reynolds stress causes lysis and
fragmentation of red blood cells leading to the release of prothrombotic agents.
Functionally, calcific aortic valve disease can be divided into two stages. The first
is calcific aortic sclerosis, in which valve leaflet thickening and calcification are present;
blood flow and leaflet mobility are not compromised 1. In contrast, calcific aortic
stenosis, the end stage of the disease, the leaflet mobility is sufficiently restricted to
impede left ventricular outflow (Figure1.7) 2, 3. Calcific aortic sclerosis is present in more
than 30% of patients over 65 years of age, with 2% showing signs of calcific aortic
stenosis. The prevalence of aortic sclerosis increases to 48% in people above 84 years.
16

Severe symptomatic calcific aortic stenosis is associated with a life expectancy of less
than 5 years.

Figure 1.7 Progression in Calcific Aortic valve disease. Morphological changes
observed in aortic-valve anatomy as result of calcification are viewed
from the aortic side with the valve open in systole. Adapted from Otto
et al 66

Although the prevalence of the disease increases with age, clinical evidence
suggests that calcific aortic valve disease does not develop due to age-related
degeneration process but is an activated cell process with identifiable clinical risk factors,
pathological characteristics, genetic factors, and molecular pathways that mediate disease
progression 4. Furthermore, several lines of evidence underline mechanical stress as a key
factor initiating the development of CAVD, as calcific lesions occur preferentially in the
fibrosa layer and correlate with areas of functional stress5. The susceptibility to lesion
formation on the aortic rather than ventricular surface of the aortic valve may result from
the higher absolute pressure and transvalvular pressure gradients present on the left side
of the heart 6. Pressure is one of the hemodynamic forces to which the aortic valve is
exposed during the cardiac cycle, and thus, hypertension is an obvious candidate for the
development of calcific aortic valve disease.
17

Potential explanations for the association of hypertension with aortic valve
disease include the possibility that hypertension results in abnormally high tensile stress
on the aortic leaflets

7, 8

. Furthermore, blood pressure is an important determinant of the

mechanical environment of the aortic valve 9. The assessment of patients with CAVD
includes the measurement of transvalvular pressure gradient and aortic valve area, as well
as assessment of left ventricular geometry and function

10

. Alternatively, effects of

hypertension may be flow dependent. Hypertension changes the flow patterns across the
valve. Acute changes in blood pressure can significantly result in turbulent flow regimes
across the valve, as a consequence of changes in transvalvular pressure gradient, resulting
in low shear stress and endothelial injury11-13. Despite the incidence of hypertension and
CAVD, it remains unknown how hypertension might influence the progress ion and
severity of the disease.
1.4.1

Clinical Risk Factors
Conventional risk factors that are characteristic of atherosclerosis such as age,

active smoking, male gender, renal failure, high low–density lipoprotein (LDL),
hypercholesterolemia, hypertension, diabetes, and metabolic syndrome are also
associated with development of CAVD
LDL in human calcified valves

17

14-16

. Clinical studies have shown high levels of

. In addition, is has been revealed that patients with

family history of hypercholesteremia also develop aortic valve lesions that calcify with
age

18, 19

. In other studies, hypertension was correlated with CAVD, as one third of

patients with calcific aortic stenosis also have concomitant systemic hypertension

20, 21

.

Although CAVD shares some histological similarities with atherosclerosis, including the
presence of oxidized lipoproteins, inflammatory cells, calcification and the production of
18

proteins by activated macrophages, there are substantial differences as well. In
atherosclerosis the clinical effects of the disease are related to the instability of the
plaques and associated formation of thrombus that can lead to other cardiovascular
episodes (i.e. stroke), in CAVD tissue calcification is more severe, the clinical effects are
associated with leaflet stiffness and narrowing at the opening of the aortic valve,
ventricular outflow obstruction, angina, ventricular overload

22

. In addition, it has been

observed that even minor calcification of the valve increases the risk of other
cardiovascular disorders (stroke, myocardial infarction) by 50%

23

. Further studies to

determine whether control of risk factors prevents CAVD appear to be necessary, as
lipid-lowering therapies and control of blood pressure have shown limited effects in the
control and progression of CAVD24.
1.4.2

Pathological Characteristics
The most critical morphological features of calcified valves include: ECM

remodeling, increased expression of pro-inflammatory cytokines, calcification,
angiogenesis, lipid deposition, and changes in valve cell phenotype 25-27 (Figure 1.8).
1.4.2.1

Lipid Deposition
One of the main histological features associated with calcifc aortic valve disease

is the presence and accumulation of lipids in calcified lesions. Further evidence showing
the involvement of lipid levels have been shown in animal models that develop
calcification secondary to a high cholesterol/high lipid diet. In addition, clinical evidence
shows that valve lesions express high levels of oxidized lipids, apolipoproteins A, E, and
B in areas of severe calcification 28-30.
19

1.4.2.2

Inflammation
Both in vitro and in vivo evidence have shown that valvular calcification is an

active process controlled by inflammatory mediators. Several histological studies
demonstrate the presence of monocytes, macrophage infiltration, T Lymphocytes, and
mast cells in early calcified lesions 31-33. These cells are normally not expressed in aortic
valve and their presence indicates the initiation of an injury response mechanism.
Additionally, it has been proven the presence of potent cytokines, chemokines and
members of the complement system in calcified valves including: IL2, IL1β, MCP-1,
ICAM-1, HLA-DR

34

. In addition, it has been shown the expression of tenasin C, a

protein involved in inflammatory responses 35. These evidences along with findings that
pro-inflammatory cytokines promote calcification in vitro further indicate that
inflammation is a crucial factor that contributes to valve calcification.
1.4.2.3

ECM Remodeling
Immunohistochemical evidence shows that calcified aortic valves present an

altered pattern of ECM remodeling. This is evidenced by the increased expression of
Matrix Metalloproteases (MMPs) and capthesins (K, V, S)

36-38

. MMPs are a family of

proteinases that regulate collagen turnover and ECM synthesis in the valve. Up regulation
of MMP3/2/9 has been found in calcified valves; furthermore it has been shown that
inflammatory cytokines (i.e IL1β, TNF-α) enhance the expression and activities of MMPs
39

. Valve ECM synthesis is dependent on the balance between MMPs and their inhibitors

TIMPs. The MMP and TIMP proteases regulate ECM remodeling through the
degradation of diverse ECM components including collagen, elastin and proteoglycans 40.
In addition, calcified valves show increased expression of capthesins, a group of
20

proteases that mediate ECM remodeling through the degradation of elastin fibers.
Dysregulation of ECM remodeling leads to valve calcification and
1.4.2.4

stiffing 41.

Angiogenesis
It has been reported that in contrast to normal heart valves, calcific aortic valve

show signs of neo vascularization in areas of bone lesion. Formation of new capillary
enhances the calcification process by facilitating the entry of inflammatory cells and
lipids to the lesion site. In addition, it has been shown that VEGF1, VEGF-A, and
VEGF1/2 receptors are present in high levels in calcified human valves

42

. The

importance of these pro-angiogenic factors resides in their capacity to promote
endothelial cells migration and proliferation required to neovascularization

43

.

Additionally, anti angiogenic factors such as chondromodulin I, SPARC and endostatin
have been found to be reduced in calcified valves, reduced levels of these factors may
lead to rapid outgrown of capillaries that facilitates bone formation in the calcified valve
44, 45

.

1.4.2.5

Osteoblast Differentiation
Histological studies suggest that CAVD may result from a process similar to that

of active bone formation. Calcified valves characterized by the presence of calcific
deposits and osteoblast like cells that express high levels of bone markers, extracellular
matrix proteins such as alkaline phosphatase, osteopontin, osteoprotegrin, bone
morphogenetic proteins , and the osteoblast-specific transcription factor CBFA-146-49.
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Figure 1.8 Pathological characteristics of aortic valve calcification.

1.4.3

Genetic Factors
Growing evidence suggests that genetic factors may not only predispose to

developmental defects such as bicuspid aortic valve but also modulate the risk of calcific
valve disease. Congenitally bicuspid aortic valve, which is present in about 0.5 to 0.8% of
the population, is the underlying anatomy dysfunction in the majority of valve
replacements for aortic stenosis50-52. Clinical evidence supports this fact, with evidence
that ≈49% valve replacement correspond to patients with congenital bicuspid valve 53-55.
Although it has been demonstrated the genetic nature of congenital bicuspid valve and its
association with calcific valve disease, the exact mode of inheritance has not been
22

elucidated

56, 57

. In addition, some epidemiological studies have shown that genetic

mutations in NOTCH1 gene, polymorphisms in the vitamin D receptor, estrogen receptor,
interleukin-10, and apolipoprotein E4 allele increase the risk of developing CAVD ,
underlining the genetic contribution in the development of CAVD 54.
1.4.4

Pharmacological Treatment
The presence of high levels of lipids and cholesterol in calcified valve lesions

have led to the novel proposal that pharmacological strategies effective in atherosclerosis,
such as hepatic hydroxymethylglutaryl coenzyme A reductase-inhibitor (statin) therapy,
might slow the progression of CAVD 58. However, recent clinical studies have shown the
limited effects of lipid-lowering statins treatment on slowing or reversing CAVD.
Another class of therapy with potential benefits in the treatment of CAVD is the use of
Angiotensin-converting enzyme inhibitors and Angiotensin 1 receptor blockers (ARBs).
Previous studies have shown high levels of members of the RAS system in human
calcified valves raising the possibility that the calcification process might be attenuated
by inhibiting the activity of ACE and blocking AT-1R. The results of these studies are
contradictory, while some clinical studies have shown reduction in the levels of
progression of CAVD; others suggest that may be used to slow the rate of progression of
the disease but not for its prevention 59. Other interesting studies show the association of
low levels of Fetuin-A and progression of aortic valve calcification. Fetuin-A is a serumbased inhibitor of calcification, and low levels of this protein in the plasma are associated
with an accelerated progression of AVC. Thus, stabilization of fetuin-A serum levels may
appear as possible approach. However, these results are based on a relatively small
patient population and a therapeutic approach has not yet been investigated 60. Although
23

several clinical evidence show that CAVD is an actively cell regulated process, and thus
it could be potentially treatable, currently there are no known pharmaceutical therapies to
prevent calcific aortic valve disease progression.
1.4.5

Signaling Pathways of Calcification
Although the mechanisms regulating aortic valve calcification are not completely

understood 61, experimental evidence shows that there are several signaling mechanisms
that are associated with the initiation and progression of aortic valve disease which
include: Renin-Angiotensin System, Wnt Signaling, TGF β signaling, and RANKL-OPG
signaling.
1.4.5.1

Renin–Angiotensin System
Recent studies suggest a role for the renin-angiotensin system (RAS) in calcific

valve stenosis progression

62-64

. The RAS signaling begins with the production of

angiotensinogen in the liver. Sympathetic stimulation, hypotension, and sodium alteration
in the plasma stimulate the release of renin by the kidney. Renin hydrolyzes
angiotensinogen to produce the inactive precursor angiotensin I. Angiotensin I is cleaved
by angiotensin converting enzyme (ACE) to yield active angiotensin II (ATII).
Angiotensin II stimulation of AT1 receptors stimulates systemic vasoconstriction and
expression of plasminogen activator inhibitor (PAI), while Angiotensin II stimulation of
AT2 receptors may cause vasodialation and apoptosis

65

. Histological evidence shows

that angiotensin-converting enzyme (ACE), Angiotensin II, and the angiotensin II type 1
receptor are up-regulated in human calcific aortic valves

66

. Importantly, Angiotensin II

(Ang II) has been shown to cause oxidative stress, inflammation, increased ECM
24

remodeling, cell proliferation, and migration of vascular and valvular cells in vitro 67. In
addition, cathepsin G and chymase

68

, two enzymatic mediators of Ang II, are also

frequently found in calcified valves . Another interesting link between valve calcification
and RAS signaling is the presence of bradykinin (BK), a potent antifibrotic agent that is
degrated by ACE, cathepsin G, neural endopeptidase (NEP). Degradation of bradykinin
results adverse ECM remodeling and fibrosis, implying that bradykinin is essential for
the functional and structural integrity of the valve

69

. Recent studies reveal that NEP is

also up regulated in calcified valves, giving more evidence of the role of RAS in valve
calcification (Figure 1.9).
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Figure 1.9 Renin- Angiotensin Signaling Pathway.

1.4.5.2

Wnt Signaling
Wnt signaling has a major role in bone mass homeostasis and development

70

.

Wnt molecules exert their functions by activating several distinct intracellular pathways,
including that mediated by β-catenin. The association between Wnt proteins, the Frizzled
family of receptors, and the low-density lipoprotein receptor-related proteins (Lrp5, Lrp6)
results in activation of β-catenin. Once activated, β-catenin is translated to the nucleus
26

where it interacts with transcription regulators essential for osteoblast development

71

.

Recently, Wnt/Lrp5 pathway was found to be activated by oxidized LDL in patients with
calcified aortic valves 72. In addition, in vitro studies show that valvular interstitial cells
express Wnt receptors, and that treatment with cholesterol leads to increased levels of
Lpr5 and β-catenin

73

. Further evidence of the involvement of Wnt signaling in

calcification has been proved in mice expressing Msx2, which is a potent transcription
factor that regulates condrocyte and osteoblast differentiation

74

. Mice over expressing

Msx2, express high levels of ALP and develop vascular calcification via Wnt- dependent
mechanism. (Figure1.10).
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Figure 1.10 Wnt Signaling Pathway.

1.4.5.3

TGF-β Signaling
The transforming growth factor β (TGF-β) family of proteins is an important

mediator of diverse signaling mechanisms in the cell

75

. TGF-β family members act by

modifying the expression of specific sets of target genes. The bone morphogenetic
proteins (BMPs) form the largest group within the TGF-β family and including BMP2,
BMP4 and BMP7

76

. BMP signaling is one of the most important pathways for bone
28

development, and differential osteoinductive activities of BMPs are elicited through
different receptors. The basic signaling cascade consists of two receptors serine/threonine
protein kinases (receptor types I and II) and a family of receptors substrates (the Smad
proteins) that move into the nucleus. The ligand assembles a receptor complex that
activates Smads, and the Smads assemble multisubunit complexes that regulate
transcription

77

. The Smad family of proteins are essential components of the TGF-β

signaling system, they play a key role in transmitting the signals of BMPs from the
activated receptors at the cell surface to the nucleus to regulate gene expression.
Receptor-mediated phosphorylation of Smads by BMPs leads to their activation
and nuclear accumulation whereby they regulate transcription of transcription factors that
promote osteoblast differentiation. Immunohistochemical studies show high levels of
TGF-β, BMP2 and BMP4 in calcified valves. In addition, it has been shown that valvular
interstitial cells stimulated with BMP2/BMP4/ BMP7 and TGF-β1 differentiate into
osteoblast like cells and form calcific nodules , underlining the potential role of TGFβ
signaling in valve calcification (Figure 1.11) 78, 79.
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Figure 1.11 TGF-β Signaling Pathway.

1.4.5.4

RANK-OPG Signaling
The receptor activator of NF-kB (RANK), its ligand RANKL and the decoy

receptor for RANKL, osteoprotegerin (OPG) are members of the cytokine system that
plays a central role in regulating bone turnover

80

. Binding of RANKL to its receptor

RANK provides the crucial signal to drive osteoclast development from haematopoietic
progenitor cells as well as to activate mature osteoclasts. OPG negatively regulates
RANKL binding to RANK and therefore inhibits bone turnover by osteoclasts. Many
factors stimulate RANKL expression including prostaglandin E2, interleukin-1 (IL-1) and
30

tumor necrosis factor α (TNFα). By contrast, estrogen or transforming growth factor β
(TGFβ) attenuates RANKL expression

81

. Some experimental data suggests that

deregulation of OPG RANKL and RANK could also affect the cardiovascular system.
For example, OPG-deficient mice show medial calcification of the aorta and renal
arteries. In addition, activation of RANK-OPL pathway in valve calcification has been
proved, as calcified valves have differential expression of RANKL and osteoprotegerin.
Further evidence of the role of RANKL/RANK signaling in valve calcification is that
stimulation with RANKL and TNF-α resulted in ECM calcification, increased expression
of alkaline phosphatase, RUNX2, and osteocalcin in valvular interstitial cells in vitro
(Figure 1.12) 82.
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Figure 1.12 RANK-OPG Signaling Pathway.

1.5

Hypertension
High blood pressure (HBP) or hypertension is a condition in which the blood

pressure in the arteries is chronically elevated 12. Hypertension affects one in three adults
in the United States and causes more than 7 million deaths worldwide each year. It is also
estimated to affect about two million American teens and children. In 2004, high blood
pressure total mention mortality was around 300,000 which is a 56.1% increase in deaths
32

since 1994

83, 84

. Although the exact causes of hypertension are usually unknown, there

are several factors that have been highly associated with the condition which includes
renal diseases, smoking, obesity, diabetes, high levels of salt intake, aging, genetic
predisposition and chronic kidney disease. In addition, hypertension can be caused by
over expression of Angiotensin II, an important member of the renin-angiotensin system
(RAS) 85.
In addition, hypertension is the leading cause of coronary heart disease, heart
failure, stroke, kidney failure and a major risk factor for calcific aortic valve disease
(CAVD). Epidemiological studies have highlighted that a large proportion (51%) of
elderly patients with CAVD also have concomitant arterial hypertension (>65years)

86

.

These studies suggest that hypertension may contribute with the development of calcific
aortic valve disease 87, 88.
Under physiological conditions in vivo, the normal mean arterial blood pressure is
approximately 80mmHg. A mean arterial pressure above 90 mmHg is considered to be
stage I hypertension. In stage II hypertension, the mean arterial pressure can rise above
150 mmHg
expectancy

89
12

. Even moderate elevation of arterial pressure leads to shortened life

. One of the principal effects of hypertension is an increase in the

transvalvular pressure gradient across the aortic valve. Pressure is one of the main forces
experienced by the aortic valve during the cardiac cycle, it has been shown to play an
important role in valve tissue homeostasis and any substantial change in the pressure
gradient can alter the mechanical environment of the aortic valve (i.e increases in
compressive and tensile forces) 90, 91. However, the mechanical effects of hypertension on
the aortic valve have not been fully defined at the cellular level.
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The Renin-Angiotensin system (RAS) is a powerful mechanism for controlling
blood pressure. This system helps to regulate arterial pressure through the release of
Renin, an enzyme that is stored in kidney cells and that is released into the renal blood
when blood pressure values are too low . Renin itself does not control blood pressure,
instead it acts as an enzymatic mediator for the conversion of angiotensinogen to
angiotensin I. Angiotensin I is a mild vasoconstrictor that in turn is the precursor of
Angiotensin II (Ang II). The conversion of Angiotensin I to Angiotensin II occurs in the
almost entirely in the lungs and it is mediated by Angiotensin Converting Enzyme (ACE)
92

.
Angiotensin II is a potent vasoconstrictor hormone that plays a central role in

hypertension; it has two principal effects that can raise the blood pressure: (1) causes
vasoconstrictor in large and small arteries, and (2) decreases the excretion of salt and
water by the kidneys, with subsequent increases in extracellular fluid blood volume and
arterial blood pressure. Elevated levels of Ang II in the blood can increase the pressure as
much as 55% above normal levels (Figure 1.13) 93.
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Figure 1.13 Renin-Angiotensin vasoconstrictor mechanism for arterial pressure
control.

Some recent studies focused on the significance of the pressure-independent
mechanism of Ang II action. However, the tissue-specific function of local Ang II is not
well understood. Evidence suggests that effects of Ang II are mediated by the
differentially expression of Ang II receptors type 1 (AT1) and type 2 (AT2). Ang II
stimulation of AT1 receptors results in proliferation of cells and stimulation of AT2
receptors results in apoptosis. Specifically, Ang II stimulation of ATR1 receptors causes
hypertension, while stimulation of AT2 and angiotensin converting enzyme 2 (ACE2)
appear to play a protective role in atherogenesis94. The regulation of RAS system with
35

Angiotensin converting enzyme (ACE) activity by ACE inhibitors and the resulting
limitation of Angiotensin II has been recognized as an essential method for maintaining
normal blood pressure as well as inhibiting cardiovascular remodeling 95, 96.
1.6

Statement of Hypothesis
The main purpose of this dissertation was to evaluate if elevated pressure can

induce osteogenic differentiation of valve interstitial cells in vitro, and if so, identify of
the potential molecular mechanisms mediating the differentiation process.
1.6.1

Hypothesis
Elevated cyclic pressure activates osteoblastic differentiation mechanisms in

aortic heart valve leading to changes in valve interstitial cells (VICs) phenotype and
activity, which can result in valve calcification and disease.
1.6.2

Specific aims
1.

Characterize phenotypic changes of valve interstitial cells from porcine

aortic heart valves exposed to simulated normotensive and hypertensive pressure for 24
hours.
2.

Identify global gene expression patterns of aortic heart valves exposed to

normotensive and hypertensive mechanical pressure using microarray technology.
3.

Identify the functional signaling pathways activated by hypertensive

pressure in aortic heart valve.
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CHAPTER 2
GENERAL METHODOLOGY
2.1

Tissue Extraction and Culture
At least 6 fresh aortic valves were obtained from a local slaughter house within 10

minutes of pig slaughter and rinse twice with ice-cold sterile Phosphate Buffered Saline
(PBS, Sigma, St Louis, MO). Valve leaflets did not shown any sign of degeneration,
tearing or calcification. To ensure that only valve interstitial cells were present in valve
tissue, endothelial cell layer was removed from each leaflet surface by immersion of
valve tissue in collagenase II 1mg/ml in serum free DMEM Worthington Biochemical
Corp.) for 5 minutes at 37OC and 5% CO2. To remove excess of collagenase II valve
leaflets were rinsed twice with PBS. Following incubated overnight in DMEM
supplemented with 10% Fetal Bovine Serum (FBS; Hyclone, Logan UT), and 1%
antibiotic/anti-mycotic solution (Sigma) prior to cyclic pressure experiments.
The endothelium significantly modulates the mechanical properties of aortic
valve leaflets. These mechanisms could regulate valve and flow dynamics and possibly
allow long-term optimal cusp function in its unique mechanical environment 1. In this
study, we used whole valve leaflets instead of valvular interstitial cells (VICs) cultures to
avoid any changes in VICs phenotype due to isolation and culture procedures. In
addition, evidence shows that VICs respond differently to mechanical stimulation when
they are isolated than when they are kept in their native valvular tissue. To obtain a pure
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population of VICs, the endothelium was removed from leaflets. Endothelial denudation
may have multiple effects on the biology of the tissue. It has been proposed that
alterations in the mechanical environment of the leaflets could be transduced into a
pathobiological response via a two-way communication system between endothelial and
interstitial cells. Denudation disrupts this communication and may expose the subendothelial interstitial cells to mechanical stimuli that they do not see when the
endothelium is intact. This limitation would also be present in cell culture; however, by
using an organ culture system VICs were retained in their native three-dimensional ECM.
The ECM is important for the transmission of mechanical signals to cells and thus, this
system has a distinct advantage over mechanical studies performed with isolated cells.
The alternative is in vivo studies. Although these have greater physiological relevance,
they do not allow for strict mechanical characterization or isolation of the effects of
pressure and/or Ang II.
Valve leaflets were placed in 6-well tissue culture plates within a custom
designed pressure bioreactor. The pressure magnitude that we have chosen in this study
corresponds to the physiological load experienced by the valve under normal and
hypertensive conditions. Based on previous studies VICs have genetic response expose to
pressure within 2 hour, and thus the gene profile at 24 hours is more likely to represent a
more prolonged exposure to pressure The frequency of 1.167Hz corresponds to the
physiological heart rate of 70 beats per minute.Each leaflet was randomly assigned to
either: (i) normotensive pressure (0-80mm Hg, 1.67 Hz) or (ii) hypertensive pressure (0120mmHg) a 1.67 Hz (sinusoidal wave; 0.6 sec influx, 0.4 sec outflux). Additionally,
temperature and pH were similar in both conditions.
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Each experiment was run for 24 hours. Upon complexion of experiments, each
leaflet was submerged in 1ml of RNA later RNA Stabilization Reagent (Quiagen) to
avoid changes in total mRNA expression and stored at 80°C until mRNA isolation.
2.2

RNA Isolation
Each leaflet was transferred directly into 600 µL of a lysis buffer containing

RNase inhibitors (Quiagen). Each leaflet was disrupted and homogenized for 30 seconds
(2000 rpm) using a rotor stator homogenizer (IKA®).Total RNA from porcine aortic
valve interstitial cells (VICs) was extracted using the RNeasy Mini kit (Quiagen,
Valencia, CA) following manufacturer’s instructions and stored at -80OC. Quality and
concentration of total RNA was determined using the Nanodrop ND-1000
spectrophotometer. mRNA samples with 260:280 ratio of 1.9 or higher were used for
Real-Time Quantitative PCR.
2.3

Real Time Quantitative –PCR
RT-PCR was carried out using iCycler iQ (Biorad) and iScript one-step RT-PCR

kit with SYBR Green (Biorad). A master mix was created using 0.25 μl SYBR® Green
One-Step Enzyme Mix, 6.25 μl 2X SYBR® Green Reaction Mix, 0.2 μl of forward and
reverse primers and RNase/DNase free distilled water to give a final volume of 11.5 μl
per sample. The master mix was pipetted into a 96-well PCR plate and 1 μl of total RNA
for each sample (between 250 and 750 ng) was added, giving a final reaction volume of
12.5 μl. cDNA synthesis and PCR amplification was performed using the following
steps: 50 oC for 30 minutes then the reaction mixture was heated to 95 oC for 5 min; a 45
cycle two-step PCR was performed consisting of 95 oC for 15 s followed by 1 min at the
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annealing temperature. Reactions were carried out using a Thermal Cycler (Bio-Rad
Laboratories, Hercules, CA). The specificity of all individual amplification reactions was
confirmed by melting curve analysis. Expression values for each gene were calculated
relative to18s mRNA levels using the∆∆CT method. Each experimental condi tion was
tested in triplicate and the mean and standard deviation were calculated to determine
changes in gene expression.
2.4

In vitro Pressure Bioreactor
To investigate the effects of mechanical pressure a custom-made, computer-

operated dynamic pressure system was designed, fabricated and used in previous studies.
The pressure system exposed tissues to mechanical stimulation by increasing the air
pressure above the supernatant media. The system consisted of: (1) a pressure chamber,
(2) a pneumatic piston, (3) a pressure transducer, (4) an electronic pressure controller
(connected to the piston) (5) a load cell conditioner and (6) a computer to control
electrical devices. The pressure chambers consist of a half-closed cylindrical stainless
steel base covered with a lid at the other end. The two pieces are bolted together to
compress a Teflon® gasket, which ensures a hermetic sealing of the chamber. The system
is able to house 2 standard 6-well tissue-culture plates.
To produce a change in the pressure within the chamber, a pneumatic piston was
integrated to the lid. As the piston moves downward in the chamber space, the Teflon
gasket stretched downward as well reducing the volume of the chamber, hence increasing
the pressure. The supply of compressed air to the piston is controlled by an electric
pressure converter, which converts electrical signal into pressure. For automatic control
of pressure, the converter was interfaced to the computer using a load cell conditioner
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(Encore Electronics, Inc., Model 4025- 101). The applied pressure was measured using a
pressure transducer (Omega Engineering, Inc., PX302-200GV) connected to the lower
side of the pressure chamber. The pressure transducer was interfaced to the computer
using also the load cell conditioner. The voltage and the pressure signal were acquired
with a data acquisition card module (Measurement Devices, PMD1608) and monitored
using a in-house developed LabView graphical user program (LABView, National
Instruments). LabView was also used to send a pressure waveform to the piston. The
applied pressure was sinusoidal 1 Hz for 24h. During experiments, the pressure system
(except for the computer and electronic components) was maintained under standard cell
culture conditions, that is 37oC, humidified, 5% CO2 and 95% air environment.
This in vitro system allowed us to study VICs behavior within an environment
characterized by different levels of extracellular pressure, which is something usual from
an in vivo environment.
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Figure 2.1 Schematic representation of the in vitro pressure system. Valve
leaflets were placed in 6-well tissue cultures plates within a stainless
steel pressure chamber and placed inside an incubator (5% CO2,
37oC) for 24 hours.
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CHAPTER 3
REGULATION OF PORCINE AORTIC VALVE INTERSTITIAL CELL PHENOTYPE
BY MECHANICAL AND BIOCHEMICAL STIMULI
3.1

Introduction
Calcific aortic valve disease (CAVD) is the leading cause of aortic valve

replacement in the elderly as it affects more than 5% of the population over 65 years old.
It accounts for a major fraction of the approximately 300,000 valve replacement surgeries
worldwide each year

1

. Calcified valves are characterized by leaflet thickening,

expression of specific bone markers and the presence of osteoblast like cells in calcific
valve lesions 2. Currently, there is no proven pharmacological treatment to stop or reverse
the morphological changes seen in calcific valves. One of the key events leading towards
the development of calcific aortic valve disease is valvular interstitial cells (VICs)
differentiation into osteoblast-like cells These cells are able to produce bone specific
proteins including osteopontin (OPN), alkaline phosphatase (ALP), osteoblast-specific
transcription factor RUNX2 and BMPs proteins 3. Multiple studies have shown that
mechanical (shear, stretch, pressure) and biochemical (TGF-β, BMP-2, BMP-7)
conditions modulate VICs biosynthetic activity and phenotype

4-6

. Specifically, BMPs

stimulation induces osteogenic differentiation of human VICs in vitro

7, 8

. These data

suggests that while VICs may play a major role in aortic valve calcification, the
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calcification process may be developed secondary to a BMP- mediated osteoblast
differentiation pathway.
Hypertension is a well known risk factor for CAVD 9, 10. Epidemiological studies
show that hypertension is present in one third of patients with calcific aortic stenosis 11,
suggesting hypertension as a potential candidate contributing to the development of
CAVD. Hypertension can be induced by over expression of Angiotensin II (Ang II), a
key member of the renin-angiotensin system (RAS) 12. Interestingly, there is evidence of
Angiotensin Converting enzyme and Angiotensin II in human calcified valves,
suggesting a role for the renin-angiotensin system in calcific valve stenosis progression
13

. Although clinically relevant, little is known regarding the molecular mechanisms by

which hypertension may contribute to the pathogenesis of calcific aortic valve disease.
Since it is likely that conditions that alter the mechanical and biochemical
environment of the valve modulate phenotypic conversion of VICs, it therefore became
of interest to understand the intracellular signals by which mechanical pressure and Ang
II might lead to phenotypic differentiation of VICs. We hypothesized that an environment
that resembles hypertensive conditions (i.e elevated pressure, Ang II treatment), induces
differentiation of VICs into osteoblast-like cells. We initially evaluated the effects of
mechanical pressure on osteogenic markers expression by exposing aortic valve leaflets
to two levels of cyclic pressure: normotensive (0-80 mm Hg) and hypertensive (0120mmHg), and then we tested the combined effects of cyclic pressure and Ang II. We
showed that elevated cyclic pressure increased the expression of genes involved in
osteoblast differentiation including the non-collagenous bone matrix proteins OPN, ALP,
RUNX2, and two essential components of the BMP osteogenic pathway: BMP-7, and
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SMAD1. The ability of these genes to promote osteoblast cell differentiation suggests
that elevated cyclic pressure may play a key role in promoting VICs differentiation into
osteoblast type cells. Additionally, expression of Ang II receptors suggests a role for Ang
II in the regulation of osteogenic differentiation of VICs.
3.2
3.2.1

Materials and Methods
Tissue and RNA Harvest
Aortic valve leaflets excised from adult female pigs were obtained at a local

slaughterhouse (Sansing Meat Services) and cultured as previously described in Chapter
2. Briefly, leaflets were rinsed in ice-cold sterile PBS (Sigma, St Louis, MO). The
endothelium was removed from the leaflet surface using collagenase II solution (2 µg/ml,
Worthington Biochemical Corp.) to simulate the in vivo pathogenic milieu. Leaflets (n=6)
were incubated overnight in DMEM in 6-well tissue culture plates. For pressure
experiments, plates were then placed in a custom pressure chamber shown in Chapter 2
and exposed to normotensive (0-80 mm Hg) or hypertensive cyclic pressure (0-120
mmHg) corresponding to diastolic transvalvular pressure in normotensive and
hypertensive conditions, at frequency of 1 Hz for 24 hours. To mimic a biochemical
hypertensive environment, culture medium was supplemented with Ang II (300nM,
Sigma) at the beginning of pressurization. Thus, four experimental conditions were
tested: (1) Valve leaflets exposed to normotensive cyclic pressure (0-80 mmHg); (2)
valve leaflets exposed to hypertensive cyclic pressure (0-120 mmHg); (3) valve leaflets
exposed to normotensive cyclic pressure with Ang II –conditioned media; and (4) valve
leaflets exposed to hypertensive cyclic pressure with Ang II –conditioned media. Upon
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completion of experiments, total RNA was extracted as previously described in chapter 2
using the RNeasy Mini kit (Qiagen). RNA quality was confirmed by electrophoresis
(2100 Bioanalyzer; Agilent Technologies, Palo Alto, CA).RNA samples with a 260:280
ratio of 1.9 or higher were used for further analysis.
3.2.2

Real Time Quantitative–PCR
Semi-quantitative reverse transcriptase polymerase chain reaction (RT PCR) was

done to measure the relative change in mRNA expression of Osteopontin (SSP1), Runt
related factor 2 (RUNX2), Alkaline Phosphatase (ALP), bone morphogenetic protein 7
(BMP-7) and Mad related protein 1 (SMAD1). Total RNA isolation, storage and RealTime RT-PCR were carried out as previously described in chapter 2. Briefly, RNA was
obtained from valve samples (n=6) with RNeasy Mini kit (Qiagen). Total RNA≈2
( µg)
was used for RT-PCR using a Bio-Rad iCycler thermocycler and iScript one-step SYBR
Green kit. Primer sequences were designed using Primer 3 software (Table 3.1)

14

.

Expression values for each gene were calculated relative to18s mRNA levels using the
∆∆CT method.
Table 3.1
Gene

Primers used for RT- PCR analysis
Accession
Number
Sense

RUNX2

Product
Size (bp)

Primer Sequence 5'-3'
Antisense

NM_001024630

CAGACCAGCAGCACTCC ATA

CAGCGTCAACACCATCATTC

344

SSP1

NM_214023

GGTCTATGGACTGAGGTCAAAATC
TA

TCCGAGGAAATAGTATTCTGTGGC

397

ALP

AY145130S2

ACCTCGTTGACACCTGGAAG

TCACGTTGTTCCTGTTCAGC

370

BMP-7

NM_001105290

GCTATGCCGCCTACTACTGC

GATGAAGTGGACCAGCGTCT

255

SMAD1

NM_213965

TGCCTCACGTCATCTACTGC

AGAGGCTGTGCTGAGGGTTA

280

18s

NM_001037146

CGGAGAGGGAGCCTGAGAAA

CGGGTCGGGAGTGGGTAAT

233
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3.2.3

Immunohistochemistry
Immunohistochemical detection of SSP1, RUNX2-1 and ALP protein expression

in aortic valve leaflets was performed. Following exposure to normotensive and
hypertensive conditions for 24 hours, leaflet samples were rinsed twice with PBS with
1% BSA, and fixed with 4% PFA (Sigma) in PBS. Additionally samples were fixed in
10% formaldehyde overnight, transferred to 70% ethanol, processed in a tissue processor,
embedded in paraffin, and cut in 5µm sections. Slides were deparaffinized, then placed in
hydrogen peroxide to inhibit endogenous peroxidase activity, and then immersed in
blocking agent for 30 minutes. Following slides were incubated overnight at 4 oC with
rabbit anti – human SSP1 (Thermo Scientific), anti–human ALP (Zigmed Laboratoties)
and anti – human RUNX2-1 (Santa Cruz Biotechnology, CA ), slides were washed in
buffer and exposed to biotinylated anti-rabbit IgG (Dako) for 30 min (Table 3.2). Cell
nuclei were counterstained with hematoxylin. The slides were observed under a
photomicroscope (Nikon) equipped with a digital camera. Images were examined with
Photoshop (Adobe Photoshop, San Jose, CA). The total amount and distribution of SSP1,
RUNX2 and ALP protein expression was compared between different samples.
3.2.4

Western Blot
Valve leaflets was disrupted and homogenized 600 µL of lysis buffer containing

in the presence of protease inhibitors (Quiagen, Valencia, CA) using a rotor stator
homogenizer (IKA®). Protein extracts from valve tissue were separated on a 10% SDS–
PAGE, and transferred to PVDF membranes (Bio-Rad Laboratories, CA). The blots were
probed with goat anti human Angiotensin II Type 1 receptor (AT1, Santa Cruz
Biotechnology,CA ) and Angiotensin II Type 1 receptor 2 (AT2, Santa Cruz
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Biotechnology, CA) specific antibodies. Proteins were detected using an HRP conjugated
anti-goat IgG secondary antibody (Santa Cruz Biotechnology, CA) and recognized by a
peroxidase chemiluminescent detection reagent (Visualizer™ Spray & Glow™,
Millipore). GAPDH (Santa Cruz Biotechnology, CA) was used as internal control (Table
3.2).
Table 3.2

Antibodies used for Immunohistochemistry and Western Blot
Target
RUNX2
ALP
SSP1
AT1
AT2
GAPDH

3.2.5

Primary Antibody
Monoclonal mouse anti-RUNX2 (US
Biological, 1:200)
Monoclonal mouse-anti ALP (US
Biological,1:200)
Monoclonal mouse-anti SSP1 (US
Biological,1:50)
Polyclonal goat anti- AT1 (US Biological,
1:200)
Polyclonal goat anti- AT2 (US Biological,
1:2000)
Polyclonal goat anti- GAPDH (US
Biological,1:200)

Secondary Antibody
Biotinylated rabbit anti-mouse
IgG
Biotinylated rabbit anti-mouse
IgG
Biotinylated rabbit anti-mouse
IgG
Biotinylated donkey anti- goat
IgG
Biotinylated donkey anti- goat
IgG
Biotinylated donkey anti- goat
IgG

Statistical Analysis
At least six experiments were run for each condition. The level of gene expression

was calculated as 2-ΔCt. ΔCt was the difference in cycle threshold between the
housekeeping gene, 18s, and the gene of interest. Results for RT PCR are reported as
mean ± 95% confidence interval. One-way analysis of variance (ANOVA) was used to
compare differences between groups; all statistical analyses were accomplished using
SAS 9.1 analysis software (SAS Institute inc. Carey, NC). A p value of 0.05 or less was
considered significant.
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3.3

Results

3.3.1

Elevated Pressure Induces Osteogenic differentiation of VICs
To determine the effect of elevated cyclic pressure on VICs phenotype, we

measured the changes in mRNA expression of three genes that induce osteosblast
differentiation:

Osteopontin

(SSP1),

alkaline

phosphatase

(ALP),

Runt-related

transcription factor (RUNX2); and two key members of the BMP osteogenic pathway:
Bone morphogenic protein (BMP-7) and Mad related factor 1 (SMAD1). The expression
levels for SSP1, ALP, RUNX2, BMP-7 and SMAD1 were significantly up regulated in
valve leaflets exposed to elevated cyclic pressure (0-120mmHg) after 24 hour treatment
(p< 0.05). Thus, SSP1 and ALP gene expression levels had a significant increase (18 and
3.8 fold change, respectively) in samples exposed to elevated cyclic pressure compared to
control samples (Figures 3.1B, C). RUNX2 levels were strikingly increased by > 2800
fold change (Figure 3.2A). Likewise, gene expression of BMP-7 and SMAD1 was
significantly increased by >700 fold (p<0.0001) in valve leaflets exposed to elevated
cyclic pressure (Figure 3.2). Given the ability of these genes to drive osteoblastic
differentiation, our data demonstrates that elevated cyclic pressure alone is able to induce
osteogenic differentiation of VICs and, further, that a BMP osteogenic pathway may be
activated.
3.3.2

Exposure to Ang II Decreases Osteogenic Gene Expression of VICs
Ang II is a potent vasoconstrictor hormone that plays a central role in

hypertension. To mimic the effects of Ang II- induced hypertension, we next investigated
the combined effects of Ang II treatment and cyclic pressure (0-80mm Hg, 0-120 mmHg)
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on osteogenic differentiation of VICs. In the presence of Ang II treatment, there was a
significant increase in SSP1, RUNX2 and ALP gene levels (2.6, 700, 5.9 fold change,
respectively) in valve leaflets exposed to elevated cyclic pressure (0-120mmHg)
compared to normotensive conditions (0-80 mm Hg) (Figure 3.1). Conversely,
stimulation with Ang II resulted in increased BMP-7 gene levels in normotensive
conditions (3.7 fold change) compared to hypertensive conditions (0-120 mm Hg).
Stimulation with Ang II significantly reduced SMAD1 gene levels in samples exposed to
elevated cyclic pressure. Furthermore, there was no significant difference in SMAD1
gene levels between normotensive and hypertensive conditions (Figure 3.2).
Interestingly, Ang II treatment suppressed the expression of SSP1, RUNX2, SMAD1 and
BMP-7 by approximately 80%, 26%, 96%, and 92%, respectively, compared with that of
the non- Ang treated leaflets exposed to elevated cyclic pressure. In contrast, ALP
expression was unchanged with Ang II treatment. This differential response to Ang II
treatment suggests a modulating role of Ang II for VICs osteogenic differentiation in
hypertensive conditions. Furthermore, there is a synergistic effect of Ang II and
hypertensive conditions to negatively regulate gene levels of transcriptional activation of
SSP1, RUNX2, SMAD1 and BMP-7 but not of ALP. To our knowledge, there are no
previous reports of Ang II-regulated gene expression of SSP1, RUNX2 and SMAD1 in
VICs.
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Figure 3.1 mRNA expression levels of osteogenic markers, relative to 18s, in
VICs exposed to normotensive (0-80 mmHg) and hypertensive
conditions (0-120 mm Hg) for 24 hours. A. RUNX2, B. SSP1 C.
ALP. Bars represent mean values + 95% confidence interval: * = p
≤0.05.
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Figure 3.2 mRNA expression levels of osteogenic markers, relative to 18s, in
VICs exposed to normotensive (0-80 mmHg) and hypertensive
conditions (0-120 mm Hg) for 24 hours. A. SMAD1. B. BMP-7. Bars
represent mean values + 95% confidence interval: * = p < 0.05.

3.3.3

Exposure to Pressure Increases Osteogenic markers in Valve Leaflets.
Immunochemical staining of porcine aortic leaflets exposed to normotensive and

hypertensive conditions in the presence or absence of Ang II showed distinct staining
patterns of RUNX2, SSP1 and ALP protein expression. In valve leaflets exposed to
hypertensive conditions RUNX2 was detected in abundance through all areas of the
leaflet (Figure 3.3 B); and treatment with Ang II markedly attenuated RUNX2 expression
(Figure 3.3 J). Complete absence of RUNX2 staining was observed in samples exposed
60

to normotensive conditions in presence and absence of Ang II (Figure 3.3 A, J). In valve
leaflets exposed to normotensive conditions, in presence or absence of Ang II treatment,
a slight staining for SSP1 was observed (Figure 3.3B, H). SSP1 expression was markedly
increased in samples exposed to hypertensive conditions (0-120 mm Hg). These samples
revealed areas of intense staining, demonstrating the enhanced accumulation of SSP1
protein in VICs (Figure 3.3E). SSP1 expression is generally lower and almost completely
absent in valve tissue exposed to Ang II under elevated pressure conditions (Figure
3.3K). ALP expression was generally absent in leaflets exposed to normotensive
conditions, and treatment with Ang II resulted in a similar pattern of staining (Figure 3.3
C, I). ALP is detected in abundance in leaflets exposed to elevated pressure. The addition
of Ang II resulted in stronger staining of ALP. Valve leaflets exposed to normotensive
conditions demonstrated low levels of ALP protein expression (Figure 3.3F,L).
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Figure 3.3 Evidence of osteogenic proteins in porcine aortic valve exposed to:
normotensive conditions (A - C); hypertensive conditions (D-F),
normotensive conditions and Ang II (G-I); hypertensive conditions
and Ang II (J-L). Representative immunohistochemical staining
(brown, shown by arrows) of RUNX2 (A,D,G,J);SSP1 (B,E,H,K),
and ALP (C,F,I,L) .Cell nuclei counterstained blue. All frames 40X
magnification.

3.3.4

Expression of Ang II Receptors in VICs
From the previous observations, we suggest that SSP1, RUNX2, SMAD1 and

BMP-7 gene expression may be negatively regulated by Ang II under hypertensive
conditions. Since downstream signaling of Ang II is dependent on specific AT receptor
expression, we therefore examined AT1and AT2 receptor expression in VICs exposed to
hypertensive and normotensive conditions by with western blot (Figure 3.4). Western
blot analysis showed that VICs exposed to normotensive cyclic pressure (0-80mmHg) or
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elevated pressure (0-120mmHg) do not express AT1, but treatment with Ang II increases
the levels of AT1 with both levels of pressure. By contrast, AT2 was detected in VICs
exposed to both normotensive and elevated cyclic pressure, and valve leaflets treated
with Ang II expressed a similar AT2 receptor profile. Because of the effect of Ang II on
osteogenic markers expression and the difference in AT1and AT2 receptor expression in
VICs to elevated pressure, we suggest that the changes observed in the expression of
osteogenic marker may be potentially mediated through the subsequent activation of the
AT1 receptor by Ang II. In addition, is interesting to find that AT2 receptor was
expressed by VICs in normotensive and hypertensive conditions, since previous findings
suggest that valve leaflets do not express AT2 receptors under normal or pathological
conditions 15, 16.

Figure 3.4 Protein expression of Angiotensin type 1 and Angiotensin type 2
receptors from valve leaflets exposed to cyclic pressure and Ang II
treatment. Lane 1. normotensive cyclic pressure (0-80 mmHg), Lane
2. hypertensive cyclic pressure (0-120 mmHg); Lane 3. normotensive
cyclic pressure Ang II (+), Lane 4. Hypertensive cyclic pressure Ang
II (+).
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3.4

Discussion
It is widely known that valve calcification is a cell-based process that requires the

mediation of an osteoblast phenotype

17

. A number of clinical studies suggest a role for

hypertension in the development of calcific aortic valve disease

10, 18

. Clinical and

experimental clues of this association include the following: Hypertension is a frequent
finding in patients with calcific aortic stenosis , elevated pressure results in alterations in
the native hemodynamic environment of the aortic valve (i.e. increased stretch,
compression of the ECM, altered flow patterns) , and calcified lesions are present on the
aortic side of the valve were higher transvalvular pressure gradients occur

19, 20

. Yet,

neither study has been able to establish the precise mechanism by which hypertension
might contribute to the development of calcific aortic valve disease.
Close correlations between mechanical loading, biochemical environment and
aortic valve biology have been demonstrated by clinical observations and animal studies
21, 22

. For example, pressure can both positively and negatively regulate systems involved

in DNA, collagen, GAGs synthesis, and activation of pro-inflammatory mechanisms 23-25.
In addition, variation in the biochemical environment (i.e. high levels of TGF-β, BMP-2)
promotes phenotypic alterations in VICs and dysregulation of ECM production 7, 19. From
these observations, it was important to evaluate the potential impact of hypertension on
molecular events that lead to calcific aortic valve disease; therefore we examined the
effects of elevated pressure and Ang II stimulation, two of the mechanical and
biochemical factors observed in hypertension, on osteogenic differentiation of porcine
aortic valvular interstitial cells.
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The most interesting finding in this study was the intense effect of elevated
pressure on VICs phenotype. Elevated pressure was able to modulate VICs osteogenic
differentiation by increasing gene expression of specific osteoblast markers SSP1,
RUNX2, ALP, SMAD1 and BMP-7. Although some changes in gene expression were
observed from biochemical stimuli with Ang II in other treatments, their effects were not
as significant as the ones obtained with the elevated pressure alone. Moreover, it was
demonstrated that the increased levels of the osteogenic markers were significantly
reduced by stimulation with Angiotensin II. To our knowledge, this is the first time that
elevated pressure is involved in regulation of VICs osteogenic differentiation via
activation of genes participating in osteoblast differentiation and BMP osteogenic
pathways. Furthermore, our results suggest possible links between Ang II signaling and
activation of osteogenic mechanisms in aortic heart valve.
3.4.1

A Major Role of Elevated Pressure in VICs Osteogenic Differentiation
We showed that elevated cyclic pressure (0-120 mm Hg), with no other

mechanical or biochemical interference, directly enhances gene and protein expression of
SSP1, ALP and RUNX2 in VICs. These are osteoblast-specific proteins, and their
expression is highly regulated in tissues undergoing bone differentiation. RUNX2, SSP1
and ALP expression is essential for maturation of osteoblasts cells and also for an
adequate mineralization of bone matrix

26, 27

. Genetic deficiency of these proteins is

associated with impaired skeletal development

28

, highlighting their key role in

osteogenic mechanisms. Hence, our results suggest that VICs, stimulated with elevated
pressure, undergo a conversion process into osteoblast-like cells. This response is
associated with an increased expression of RUNX2, SSP1, and ALP. In addition, our data
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demonstrates that physiological levels of pressure are capable to maintain VICs
phenotype, as basal gene levels of RUNX2, SSP1, and ALP were detected in VICs
exposed to normotensive pressure (0-80 mm Hg). It has been previously reported that
treatment with exogenous BMP-2/BMP-7 causes osteogenic differentiation of VICs in
vitro

3, 29

. This finding along with evidence that severely calcified aortic valves contain

increased levels of RUNX2, OPN, and ALP

3, 30

confirms the contribution of active

osteogenic regulatory pathways in valve calcification.
Further evidences of an osteogenic transformation of VICs exposed to elevated
pressure are the increased levels of SMAD1 and BMP-7. SMAD1 is one of the three
known receptor-regulated Smads (R-smad); it has been widely studied due to its function
as a key transcriptional regulator for multiple genes related to osteogenic mechanisms
including OPN and RUNX2

31

. In fact, association of SMAD1 and RUNX2 is required

for the progression necessary for the osteoblast differentiation in mesenchymal stem cells
in vitro 27. Studies show that SMAD1 regulation of RUNX2 and OPN is induced by bone
morphogenic proteins in human VICs7. In addition, SMAD1 expression is an indicator
for signaling through BMP pathways. BMP-2 and BMP-7 are well known growth factors,
and their effects in osteogenic induction have been thoroughly studied. Consistent with
this idea, we found increased expression of BMP-7 gene levels in VICs exposed to
elevated pressure. Bone Morphogenetic Protein 7 (BMP-7) belongs to the TGF-beta
family; they promote phosphorylation and activation of SMAD proteins through diverse
types of BMP receptors. Both BMPs and SMAD proteins are the major mediators of
specific osteoblastic differentiation 28, 32. The ability of these genes to promote osteoblast
differentiation suggests that elevated pressure may have a key role in promoting VICs
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differentiation into osteoblast type cells through BMP-mediated signaling. Taken together
these findings demonstrate that elevated pressure is able to activate the transcriptional
regulation of genes that are essential for osteoblast differentiation pathways in VICs.
Hence, elevated pressure through increased expression of BMP-7 and SMAD1 may
induce the expression of the osteoblast specific genes RUNX2, SSP1 and ALP and
together may function in a positive feedback loop to induce osteoblastic differentiation in
VICs (Figure 3.5).
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Figure 3.5 Schematic representation of and molecular interactions and cellular
location among significantly expressed genes involved in BMP
osteogenic signaling pathway. Nodes are displayed using various
shapes that represent the functional class of the gene product: Y
shaped figures represent transmembrane receptors; down-pointing
triangles represent cytokines, horizontal ovals represent transcription
regulators. Continuous lines show direct interactions between nodes
and dashed lines show indirect interactions. Lines beginning and
ending on the same node show self regulation. Arrowheads show
directionality of the relationship. SPP1 is the alternative name of
SSP1.

3.4.2

Regulatory Role of Ang II in VICs Osteogenic Differentiation
It has been reported that Angiotensin converting enzyme (ACE), Angiotensin II,

and the Angiotensin II type 1 receptor (AT1) are up-regulated in human calcified aortic
valves, suggesting a role for Ang II in valvular calcification 33. Angiotensin II is a potent
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vasoconstrictor hormone that plays a central role in hypertension. The effects of Ang II
can be triggered by the binding to two types of receptors: Ang receptor type 1 (AT1) or
Ang receptor type 2 (AT2). Both exert opposite effects as AT2 has a pro apoptotic role,
which contrasts with the proliferative role of AT1. After binding to receptors, Ang II may
stimulate different signaling pathways 12. Based on these observations, it was therefore of
interest to define the effects of Ang II in VICs osteogenic differentiation by cyclic
pressure. Our data shows that the increase in OPN, RUNX2, SMAD1, and BMP-7
induced by elevated pressure in VICs was markedly attenuated with Ang II treatment.
Specifically in VICs exposed to elevated pressure, Ang II suppresses BMP-7, OPN, and
SMAD1 gene expression, whereas ALP was not affected. In addition, stimulation with
Ang II did not completely inhibited RUNX2 expression. This response may partially
result from differential expression of Ang II receptors in VICs. Here, we demonstrated
that AT1 was expressed on VICs exposed to elevated cyclic pressure and Ang II. In
addition, we showed that VICs expressed AT2 receptors independently of the pressure
conditions. These data suggest that factors that modulate osteogenic conversion of VICs
are associated with up-regulation of Ang II type 1 receptors. In vitro studies have
suggested that Angiotensin type 1 and type 2 receptors exhibit opposite functions, thus,
AT2 receptors appear to induce pro apoptotic mechanisms that contrast the cell
proliferative effects of AT1. It is widely known that AT1 is responsible for most of the
effects of Ang II in hypertension. In addition, AT1 receptor and expression of Ang II
converting enzyme expression has been proved in VICs from calcified valves

34

. It has

been suggested that the negative effects of AT1 activation might also relate to oxide
radical generation, as AT1 receptor activation can lead to up regulation of NADPH
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oxidase 35, a mechanism for generation of superoxide and elevation of oxidative stress. In
conclusion our findings suggest that: (1) elevated pressure may induce VICs osteoblast
differentiation by activating other SMAD/BMP independent signaling for RUNX2/ALP
expression (i.e. TNF-α/ cAMP signaling), (2) Ang II may regulate VICs osteogenic
differentiation by negative feedback in SMAD1/BMP-7 signaling, and (3) Ang II type 1
receptor levels may be a determining factor on valve calcification. Our results contrast
with previous studies which show that Ang II-stimulation via AT1 significantly increases
OPN levels and SMAD1 activation in vascular interstitial cells

36

; and thus, the

differential response to Ang II treatment underlines the phenotypic and functional
differences of VICs with their vascular counterparts. We suggest that AT1 II signaling
may decrease the levels of osteogenic markers (SMAD1, SSP1) in VICs by two possible
mechanisms: (i) through an inhibitory effect on SMAD1 activation or (ii) inducing VICs
redox-mediated apoptosis.
Our data regarding AT2 expression are intriguing. Although, it is widely known
that AT1 is responsible for most of the effects of Ang II in hypertension, the effects of
AT2 are still controversial. Previous data show that AT2 receptor is abundant in
atherosclerotic lesions and also AT2 expression increases in hypertensive mice

37, 38

.

However, pharmacological disruption of AT2 leads to accelerated atherosclerosis 3.
These findings suggest that AT2 expression can itself be a way to moderate the
pathophysiological actions of AT1, giving AT2 protective role in hypertension 4. To our
knowledge this is the first study that shows expression of AT2 receptors in VICs. The
disparity between our results and those of other reports may be partly explained by the
time and conditions in which valve leaflets were exposed to pressure. However,
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expression of AT2 receptors in VICs could play a significant role in the pathogenesis of
calcific aortic valve disease, and thus, further studies into the effects of AT2 in VICs are
needed.
The close association between high levels of osteogenic markers (RUNX2, ALP,
SSP1,BMP-7,and SMAD1) and elevated pressure raises the question whether osteogenic
differentiation of VICs is the result of direct transmission of mechanical loading by ECM
to VICs (i.e via integrins, membrane receptors) or through activation of secondary
processes (i.e. oxidative stress). Although, our study does not address this question,
several studies show that oxidative stress promotes a phenotypic shift of vascular smooth
muscle cells from contractile to osteogenic phenotype 39. In addition, oxidative stress is
present in all forms of hypertension and also it is increased in human calcified valves
41

40,

. Interestingly, it has been shown that BMP expression can be regulated by oxidative

stress 28. Hence, it is possible that oxidative stress, induced by elevated pressure, might be
able to stimulate BMP osteogenic signaling pathways in valve leaflets leading to VICs
osteogenic differentiation. Future work will be needed to determine specific links
between mechanisms of oxidative stress and activation of osteogenic mechanisms in
VICs exposed to elevated cyclic pressure. Although hypertension may not be the only
factor leading to the development of aortic valve calcification, our results show that
elevated cyclic pressure may promote the development of a calcified lesion by directly
influencing VICs osteogenic differentiation. Furthermore, our data demonstrates that
hypertensive pressure is a key regulator of VICs phenotype via promoting osteogenic
differentiation through a BMP pathway into an osteoblast-like phenotype. In addition, we
suggest that Ang II through AT1 receptors play a regulatory role in osteogenic
71

differentiation mechanisms in VICs. Further studies are required to elucidate the possible
links between mechanisms of Ang II receptors and osteogenic differentiation of VICs.
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CHAPTER 4
FUNCTIONAL MODELING OF PRESSURE INDUCED GENE EXPRESSION
REVEALS MECHANOSENSITIVE SIGNALING PATHWAYS
IN THE AORTIC VALVE
4.1

Introduction
Non-rheumatic aortic valve disease is characterized by chronic inflammation,

increased extracellular matrix (ECM) remodeling, proliferation and differentiation of
valvular interstitial cells (VICs) and the development of calcific lesions on the valve1, 2.
Evidence shows that pathological changes in valve tissue can be triggered by an altered
hemodynamic environment, underlining the importance of mechanical loading in valve
structure and function

3, 4

. Numerous epidemiological and histological studies have

suggested hypertension as a contributing factor for the development of aortic valve
disease

5, 6

. The potential mechanisms connecting hypertension with initiation and

progression of aortic valve disease include: (1) hypertensive pressure raises the diastolic
transvalvular pressure across the valve, increasing the mechanical strain experienced by
the valve; (2) hypertension may disturb the hemodynamic environment, thus influencing
valve cell behavior; and (3) hypertension may play a key role in the activation of several
biological processes that induce aortic valve remodeling and disease 7. Furthermore, a
number of in vitro models have shown that cyclic pressure plays an important role in
valve ECM synthesis, pro-inflammatory and capthesin gene expression 8-11. In addition, it
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has been reported that transvalvular pressure has a direct effect on VICs stiffness and
collagen synthesis

12

. These findings suggest that a causal relationship exists between

increased cyclic pressure and the pathogenesis of aortic valve disease. However, the
mechanisms by which mechanical pressure acting on VICs leads to signaling regulation,
gene expression, and ECM modulation remain unclear. Our hypothesis is that elevated
pressure plays a key role in the development of aortic valve disease by activating
inflammatory

and

valve

remodeling

mechanosensitive

pathways.

To

identify

transcription factors, regulatory genes and molecular mechanisms underlying valve
response to elevated pressure, we used Affymetrix porcine microarrays and compared
global gene expression profiles of porcine aortic valve leaflets exposed to cyclic
pressures of 0-80 or 0-120 mmHg for 24 hours, representing physiological normotensive
and hypertensive diastolic transvalvular pressure, respectively. Here, we showed that
elevated pressure plays a critical role in the transcriptional regulation of pro-apoptotic
and ECM remodeling mechanisms in aortic valve tissue, which are important factors in
the development of aortic valve disease. These processes are associated with the
expression of several pro-inflammatory genes, matrix metalloproteases (MMPs) and proapoptotic genes. Taken together, our data provides valuable evidence of the relevant
molecular mechanisms activated by elevated cyclic pressure that have been previously
observed in aortic valve disease.
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4.2
4.2.1

Materials and Methods
Tissue Culture and RNA Harvest
Aortic valve leaflets excised from adult female pigs were obtained at a local

slaughterhouse (Sansing Meat Services) and cultured as previously described in Chapter
2. Briefly, leaflets were rinsed in ice-cold sterile PBS (Sigma, St Louis, MO). The
endothelium was removed from the leaflet surface using collagenase II solution (2 µg/ml,
Worthington Biochemical Corp.) to simulate the in vivo pathogenic milieu. Leaflets were
incubated overnight in DMEM in 6-well tissue culture plates (n=3). For pressure
experiments, plates were then placed in a custom pressure chamber shown in Chapter 2
and exposed to normotensive (0-80 mm Hg) or hypertensive cyclic pressure (0-120
mmHg) at frequency of 1 Hz for 24 hours. Upon completion of experiments, total RNA
was extracted as previously described in Chapter 2 using the RNeasy Mini kit (Qiagen).
RNA quality was confirmed by electrophoresis (2100 Bioanalyzer; Agilent Technologies,
Palo Alto, CA).
4.2.2

cDNA Microarrays
All protocols for RNA target preparation and hybridization were as described in

the Affymetrix GeneChip Expression Analysis Technical Manual (Affymetrix, Santa
Clara, CA). Briefly, total RNA (~70 ng of mRNA) was used for linear, two-cycle
amplification by in vitro transcription and a total of 10 µg of single stranded cRNA was
hybridized to GeneChip® Porcine Genome Array following the manufacturer’s set
protocol (Affymetrix). The array data and images were collected with the Affymetrix
GeneChip Scanner 3300.
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4.2.3

Microarray Data Analysis
mRNA expression levels were evaluated using the microarray software

(Microarray Suite ver. 5.0; Affymetrix), which calculated three detection levels (present,
marginal, absent) and the size of the messages, by considering both the intensities of the
signals which were emitted from the probe sets and the number of probe pairs in which
the perfect match was specific. The signal intensities for all probes in of each microarray
were normalized and log transformed. The t test with the option of unequal variance was
used to calculate P values for each gene. The fold change and Q values for each gene
were calculated with SAM program with permutation of 500

13

. A p value < 0.05 was

considered statistically significant.
4.2.4

Gene Ontology Analysis and Data Modeling
Porcine genes with no existing Gene Ontology (GO) annotation were manually

GO annotated based on sequence similarity to human proteins using GOanna 14 to search
against the UniProtKB database15. To model the dataset, GO terms for differentially
expressed (DE) genes were grouped based on the three organizing principles of GO:
Cellular Component (CC), Molecular Function (MF) and Biological Process (BP). Each
category was subjected to high-level analysis using the GOA whole protein SlimViewer.
In addition, a specific set of GO Biological Process terms were selected based on their
relevance to aortic valve disease (Table 4.1). Gene products within each GO term were
scored to have a quantitative value of their changes in valve tissue that was exposed to
elevated pressure. Ingenuity Pathways analysis (IPA; www.ingenuity.com) was used to
identify statistically overrepresented interactions and pathways for our DE dataset. Since
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IPA database does not include porcine genes, human orthologs of porcine genes were
manually searched for in UniprotKB database and used as input gene identifiers in IPA.
Table 4.1

Selected GO Biological Processes with differentially expressed genes
associated with aortic valve disease.
GO ID

4.2.5

GO Term Description

GO:0048771

tissue remodeling

GO:0034103

regulation of tissue remodeling

GO:0030198

extracellular matrix organization

GO:0043085

positive regulation of catalytic activity

GO:0043086

negative regulation of catalytic activity

GO:0008284

positive regulation of cell proliferation

GO:0008285

negative regulation of cell proliferation

GO:0030154

cell differentiation

GO:0045595

regulation of cell differentiation

GO:0045597

positive regulation of cell differentiation

GO:0045669

positive regulation of osteoblast differentiation

GO:0050729

positive regulation of inflammatory response

GO:0002376

immune system process

GO:0002526

acute inflammatory response

GO:0002684

positive regulation of immune system process

GO:0001818

negative regulation of cytokine production

GO:0001819

positive regulation of cytokine production

GO:0006915

Apoptosis

GO:0043065

positive regulation of apoptosis

GO:0043069

negative regulation of programmed cell death

GO:0043068

positive regulation of programmed cell death

GO:0043066

negative regulation of apoptosis

GO:0006916

anti-apoptosis

GO:0006917

induction of apoptosis

GO:0045768

positive regulation of anti-apoptosis

GO:0019987

negative regulation of anti-apoptosis

Real Time Quantitative–PCR
Microarray-based differential mRNA expression of MMP-3, MMP-1 and IL-6

was validated using semi-quantitative real-time RT-PCR. Total RNA isolation, storage
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and Real-Time RT-PCR were carried out as previously described in chapter 2. Briefly,
RNA was obtained with RNeasy Mini kit (Qiagen). Total RNA (≈2 µg) w as used for RTPCR using a Bio-Rad iCycler thermocycler and iScript one-step SYBR Green kit. Primer
sequences were designed (Table 4.2) using Primer 3 software

16

. Expression values for

each gene were calculated relative to18s mRNA levels using the ∆∆CT method.
Table 4.2

Primers used for RT- PCR validation

Gene

MMP3
MMP1
IL6

4.2.6

Accession
Number

NM_001166308
NM_001166229
NM_214399

Fragment
Size (bp)

Primer Sequence 5'-3'
Sense

Antisense

TGTGGAGTTCCTGATGTTGG

GGCTGAAGTCTCCGTGTTCT

240

TTTCCTGGGATTGGCAAC

TCCTGCAGTTGAACCAGCTA

233

CACCAGGAACGAAAGAGAGC

GTTTTGTCCGGAGAGGTGAA

204

Microarray Quality Check
Metrics like noise, background, Scale factor, and the ratio of intensities′ of 3

probes to 5′ probes for Actin and GAPDH genes were analyzed for chip quality control.
Spiked in controls (B. subtilis genes lys, phe, thr, and dap) were added to the total RNA
at known concentrations at the beginning of the experiment. Their intensity values were
used to monitor the linear amplification and labeling process. The performance of the
hybridization control genes (E. coli genes BioB, BioC and BioD and P1 Bacteriophage
cre) was also used for determining the quality of each chip.
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4.3
4.3.1

Results
mRNA Isolation
The amount of total mRNA isolated from aortic valve leaflets (n= 6) was between

50-70 ng per sample. RNA integrity number (RIN) ranged from 1.8 to 2.0, based on the
ratio between the 28S and 18S ribosomal RNA bands from the Bioanalyzer gel-like
image (Figure 4.1).

Figure 4.1 The image shows a total mRNA gel like-image produced by the
Bioanalyzer. (Six samples used in the microarray experiment are
shown). Lane L: Size markers. Lanes 1-3: total mRNA from valve
leaflets exposed to normotensive cyclic pressure (0-80 mmHg), Lanes
4-6: total mRNA from valve leaflets exposed to hypertensive cyclic
pressure (0-120 mmHg). The 28S and 18S distinctive ribosomal RNA
bands are observed for all samples.
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4.3.2

Differential Gene Expression in Elevated Pressure Conditions
Transcriptome analysis of porcine aortic valve tissue was performed to determine

the distinct genetic profile of valve tissue exposed to 0-80 mmHg (normotensive/control)
and 0-120 mmHg (hypertensive) cyclic pressure. Microarray experiments were
performed in three biological replicates for both experimental conditions. A set of 1441
genes was identified as differentially expressed (DE) in hypertensive conditions
compared to controls. Of these, 735 transcripts (≈ 51%) were significantly increased (p
<0.05) in valve tissue exposed to elevated pressure compared to valve tissue exposed to
control pressure. In addition, valve tissue exposed to elevated pressure had 706
transcripts (≈49%) whose levels were significantly decreased compared to controls.
Because our hypothesis states that elevated pressure activates inflammatory and valve
remodeling mechanisms in valve tissue, we confirmed our microarray results by verifying
the expression of three genes associated with ECM remodeling and inflammation: Matrix
metalloproteinase-3 (MMP-3; 134 fold change), Matrix metalloproteinase-1 (MMP-1;
7.99 fold change) and Interleukin-6 (IL6; 10 fold change) using quantitative RT- PCR.
MMP-3 and MMP-1 expression levels were consistent with our microarray results (p
<0.05); however, IL6 levels were increased by a much greater degree than in the
microarray data (Figure 4.2).
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Figure 4.2 Real-time PCR validation of microarray data. Gene expression
patterns from microarray analysis (dark bars) and semi-quantification
through RT-PCR (clear bars). Values represent fold change in gene
expression of samples in hypertensive conditions relative to
normotensive conditions.

4.3.3

Improved Annotation of the Pig Genome
Interpretation of functional genomics data (including array datasets) relies on both

structural and functional annotation of gene and gene products. Structural annotation is
the demarcation of functional elements within genomic sequence while GO functional
annotation attributes known processes, functions and cellular locations to those same
structural elements. Only 12% of the DE porcine transcripts had GO-annotation based on
pig genes. However, of the transcripts with no GO, 27% had similarity to genes from
other species based on probe classification from NetAffx analysis center (Affymetrix).
Sequence homology was used to add GO annotation for 545 transcripts with incomplete
GO functional annotation, bringing the total number of GO annotated transcripts to 37%.
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The remaining 718 DE transcripts did not meet our homology cut off criteria (See
Materials and Methods). A set of 723 DE transcripts was used for further GO and IPA
analysis. The complete list of DE transcripts can be accessed in the GEO database
(http://www.ncbi.nlm.gov/geo/GSE15211) and functional annotation has been submitted
to the AgBase database where they will be made publicly available.
4.3.4

Functional Modeling
Analysis of DE genes through GO was conducted to allow detection of biological

processes affected during exposure of valve tissue to hypertensive pressure. Therefore,
GO Cellular Component (CC) shows that a large number of increased DE transcripts are
located in the extracellular region (61%) and membrane (56%), compared to normal
samples (Figure 4.3). These results suggest that high pressure induces changes in valve
architecture through increased expression of ECM structural components. Analysis of
GO Molecular Function (MF) indicates that under high pressure, there is an increase in
the number of genes involved in protein binding activity, catalytic activity, nucleic acid
binding activity and signal transducer activity (Figure 4.4). Up-regulated genes in the
hypertensive samples were predominantly genes involved in catabolic and proteolytic
activity, with specific roles in ECM remodeling

17

. In addition, changes in nucleic acid

binding and signal transducer activity suggest activation of transcriptional mechanisms
and activation of VICs. Notably, antioxidant activity and translation regulator activity
were only found in hypertensive samples. Furthermore, oxidoreductase activity was
decreased, suggesting valve tissue vulnerability to reactive oxygen species and activation
of pro-inflammatory mechanisms.
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Analysis of GO Biological Process (BP) showed several processes that were
consistent with our hypothesis of alteration in inflammatory and valve remodeling
mechanisms, but also distinct biological processes such as transport, secretion, cell
motion, cell communication, cell differentiation and cell death were affected by elevated
pressure (Figure 4.5).

Figure 4.3 Cellular localization of differentially expressed transcripts from
hypertensive tissue. GO Cellular Component annotations were
summarized to broad level terms using the GOA whole proteome GO
Slim set.The net regulatory effect was determined by subtracting the
number of decreased proteins from the number of increased proteins
in each GOSlim category.
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Figure 4.4 Molecular Functions of differentially expressed transcripts from
hypertensive tissue. GO Molecular function annotation were
summarized to broad level terms using the GOA whole proteome GO
Slim set.The net regulatory effect was determined by subtracting the
number of decreased proteins from the number of increased proteins
in each GOSlim category.
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Figure 4.5 Biological Process of differentially expressed transcripts from
hypertensive tissue. GO Biological Process were summarized to
broad level terms using the GOA whole proteome GO Slim set.The
net regulatory effect was determined by subtracting the number of
decreased proteins from the number of increased proteins in each
GOSlim category.
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Figure 4.6 Potential biological processes involved in valve remodeling.
Comparison of gene expression levels of four potential valve
remodeling mechanisms suggested by hypothesis-driven GO
modeling.

We used hypothesis–driven GO analysis (see Materials and Methods) to
specifically examine the role of four biological processes associated with aortic valve
disease: ECM remodeling, inflammation, cell differentiation and/or proliferation and cell
death (Table 4.1)18. GO-modeling showed an overall increase in ECM remodeling,
inflammation, cell differentiation and pro-apoptotic activity in VICs exposed to
hypertensive pressure (Figure 4.6). Consistent with our hypothesis, all the differentially
expressed genes from our data set within the GO BP categories of ECM organization,
inflammatory response, cell death, cell differentiation were mapped into signaling
networks with IPA on networks. Therefore, two major networks were chosen (i) TP53
network and (ii) Cell death network. The TP53 network (Figure 4.7) shows the
90

interaction of a number of genes implicated in a broad range of biological processes,
including

ECM

remodeling

(MMP-1,MMP-3,TIMP-1,TIMP3),

pro-inflammatory

mechanisms (IL-8, IL-6, IL-1β, IL-1A), immune-related genes (MCP-1, ICAM-1, SELP,
SELL,) and antioxidant mechanisms (SOD2, GPX7), but that are transcriptionally
regulated by Tumor suppression factor TP53. Importantly, some of these genes are
associated with the development of aortic valve disease 19. In addition, TP53 represses
the expression of genes that promote cell cycle progression. The cell death network
(Figure 4.8) consists of a set of interconnected genes involved in pro apoptotic
mechanisms. In particular, the association of pro-apoptotic genes (CYCS, FAS, CASP3,
CASP7, CASP8) with genes that have a predominantly negative effect in the occurrence
of apoptosis (BIRC3, BIRC2, BIRC5) was observed. These genes are involved in specific
pro-apoptotic pathways and are of particular interest given that apoptosis is a rare process
in normal aortic heart valves; in contrast, in aortic valve disease the occurrence of
apoptosis increases20. Interestingly, the tumor suppressor gene TP53 also positively
regulated genes involved in the initiation of apoptosis.
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Figure 4.7 TP53 network. The network shows molecular interactions among
significantly expressed genes involved in cell inflammatory response,
ECM remodeling, oxidative stress and the transcription factor TP53
under elevated pressure conditions. Green color represents a decrease
and red represents an increase in gene expression. Nodes displayed
represent the functional class of the gene product: down-pointing
triangles represent kinases; diamonds represents enzymes, horizontal
ovals represent transcription regulators; and circles represent other
types of molecules. Continuous lines show direct interactions
between nodes and dashed lines show indirect interactions. Lines
beginning and ending on the same node show self regulation.
Arrowheads show directionality of the relationship.
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Figure 4.8 Cell Death network. The network shows the molecular interactions
among significantly expressed genes involved in pro apoptotic
mechanisms in which gene expression was altered by elevated
pressure. Symbols are as described in the legend for figure 4.7.

4.4

Discussion
Multiple molecular and cellular mechanisms are associated with the initiation and

progression of aortic valve disease. Well-documented manifestations of aortic valve
disease associated with alterations in valve architecture include increased ECM
remodeling, expression of pro-inflammatory cytokines, calcification, lipid deposition and
changes in valve cell phenotype 21. In vitro models are used to demonstrate the regulatory
role of mechanical stimuli in valve structure and cellular function. Specifically, it has
been shown that mechanical loading (e.g. shear, tension etc) promotes changes in
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expression levels of a set of genes involved in ECM synthesis, cell differentiation and
DNA synthesis in valve cells

9, 21-23

. These changes may be caused by the activation and

inactivation of specific regulatory mechanisms related to ECM remodeling and cell
activation. However, none of the current models evaluates the molecular mechanisms
leading to these changes and whether or not elevated pressure plays a critical role.
In the present study, we used a combination of GO-based and pathway-based
analyses to identify novel genes and molecular mechanisms that are activated in valve
tissue during exposure to elevated pressure conditions. Our results show that elevated
pressure induces a gene expression pattern in valve tissue that is considerably similar to
that seen in aortic valve disease, underlining the key role of hypertension as an initiating
factor in the onset of pathogenesis. In addition, our analysis revealed a set of genes that
were not previously known to be regulated in valve tissue in a pressure dependent
manner. In particular, this set of genes is associated with two highly connected networks;
the TP53 network, and the cell death network. These networks are associated with an
increase in ECM remodeling, inflammation and apoptotic mechanisms. Modeling these
networks has facilitated the discovery of some very specific genes that could potentially
be targeted for the treatment of aortic heart valve disease.
4.4.1

TP53 Network
TP53 is a tumor suppressor gene that controls cell cycle progression, cell growth

and apoptosis through transcriptional activation of matrix metalloproteinases (MMPs),
cytokines, proteases, growth factors, etc. TP53 can be activated by several signals,
including oxidative stress 24. Our findings show that exposure of valve tissue to elevated
pressure induces TP53 over expression and the expression of a number of TP53 target
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genes. These genes include, among others, ECM remodeling enzymes, pro-inflammatory
cytokines and oxidative stress enzymes. TP53 induction by elevated pressure increases
valve ECM degradation by stimulating promoter activity of MMPs and decreasing the
expression TIMPs 25. These findings indicate that TP53 is an important mediator of valve
remodeling mechanisms. Specifically, it suggests that TP53 may contribute to valve
dysfunction by altering the expression of genes that participate in ECM turnover. To our
knowledge this is the first study to show TP53 gene expression is activated by pressure in
aortic valve tissue.
The role of TP53 in the transcription of a number of genes predicted to generate
or respond to oxidative stress has been revealed in multiple studies

26

. It has been

proposed that these genes can induce oxidative stress leading to TP53-dependent
apoptosis. Our findings show that elevated pressure induced the expression of two of
ROS associated genes: superoxide dismutase 2 (SOD2) and Glutathione peroxidase 7
(GTX7). The SOD2 gene has a specific role in ROS production, whereas the GTX7 gene
is associated with ROS degradation. Both genes have been shown to be actively regulated
by TP53

27

. Elevated pressure induces an increase in SOD2 gene levels, which contrast

with decreased levels of GPX7 gene expression in valve tissue. Our results strongly
suggest that there is an imbalance in the antioxidant enzyme system of VICs.
Furthermore, it may contribute to an oxidative stress response followed by an increase in
apoptosis in the valve after exposure to elevated pressure. Of particular interest in this
network is the increase of the SOD2 and TP53 genes. Studies have shown SOD2
expression to be increased following death receptor activation that is activated by TP53
28

. Thus, it is unclear if the antioxidant mechanism and ROS production are a cause or a
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consequence of TP53 pro-apoptotic mechanism. It will be necessary to determine the
potential involvement of elevated pressure in the production of reactive oxygen in a time
dependent manner to fully understand the relationship between SOD2 and TP53 gene
expression in heart valves. These data show conclusively that TP53 is the key effector in
the transcriptional cascade regulating valve tissue pro-apoptotic and ECM remodeling
mechanisms in response to elevated pressure.
4.4.2

Cell Death Network
Apoptosis plays an important role in normal tissue homeostasis. Specifically,

normal valve tissue homeostasis is dependent on the balance between cell proliferation
and death of VICs

22, 29

. However, any imbalance can result in undesirable apoptosis or

cell growth of VICs. If activated VICs do not undergo apoptosis, excessive ECM
deposition may occur leading to valve dysfunction. Therefore it is of interest to attempt to
understand the intracellular signals by which elevated pressure might stimulate proapoptotic mechanisms in valve tissue. The molecular mechanisms underlying apoptosis
in cells are complex and only partially understood. Two main mechanisms have been
identified: (i) the extrinsic or death receptor pathway, which requires stimulation of
membrane receptors (eg. FAS, TGF-β, etc) by their ligands and (ii) the intrinsic
mitochondrial pathway, which requires binding of the Bcl-2 family members to the
mitochondrial membrane. Both mechanisms converge in the activation of several
members of the caspase family, release of cytochrome c, and the initiation of proapoptotic mechanisms. Furthermore, both mechanisms can be activated by diverse stimuli
(e.g. oxidative stress, TP53 activation, growth factors). Cross talk between the
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mitochondrial and extrinsic pathway is possible through activation of the pro-apoptotic
proteins BID or BAX via TP53.
Our results show that elevated pressure triggered the expression of several genes
that are involved in different steps of the death receptor pathway including FAS receptor,
three members of the caspase family (CASP1, CASP7, CASP8) and cytochrome C.
These genes are transcriptionally regulated by TP53, thus the death receptor pathway is a
TP53-dependent apoptosis pathway. Considering the fact that oxidative stress has been
shown to modulate TP53 activity, and that TP53 regulates FAS receptor-mediated
apoptosis, the increased FAS gene expression may be expected to be associated with the
increased expression of TP53 and the induction of ROS by elevated pressure. In addition
to the death receptor signaling triggered by elevated pressure, increased expression of
BID, a pro-apoptotic Bcl-2 family member, suggest that there might be cross-talk
between the two pathways and that they are activated by elevated pressure. Furthermore,
our data suggests that an anti-apoptotic mechanism was altered. We observed decreased
expression of genes involved in negative regulation of apoptosis, such as BIRC5. This
transcription factor belongs to the IAP family, which is a potent caspase inhibitor and is
required to maintain a balance between cell proliferation and apoptosis. Thus, elevated
pressure

was

able

to

activate

pro-apoptotic

and

anti-apoptotic

mechanisms

simultaneously in aortic valve tissue. The enhanced expression of pro-apoptotic genes in
VICs indicates that cell turnover is another important mechanism influenced by elevated
pressure. Furthermore, it suggests dysregulation of mediators of apoptosis in valve tissue
that favors apoptosis.
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Although pressure is one of the main components of the valvular environment,
the effect of elevated pressure on VICs has not previously been thoroughly examined.
Our results show that pressure plays a critical role in the regulation of valve tissue
homeostasis. Together, the microarray analyses with IPA suggest strongly that TP53
plays an essential role in regulating genes that promote ECM synthesis and apoptosis in
valve tissue in a pressure dependent manner. Furthermore, the genetic profiles of valve
tissue exposed to elevated pressure share common abnormal genetic features observed in
aortic valve disease, providing validation to our experimental model. Changes in gene
expression levels related to the inflammatory response, ECM remodeling and cell death
occurring in elevated pressure conditions were attributed to the activation of VICs as a
response to increased mechanical loading. Our results suggest that the valve remodeling
mechanisms activated by elevated pressure could lead to the development of aortic valve
disease.
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CHAPTER 5
SUMMARY AND CONCLUSIONS

Calcific aortic valve disease is one of the most complex cases of cardiac diseases.
If untreated, progression of the disease leads to 50-60% mortality rate following year
onset of symptoms. Despite the high prevalence and the increasing morbidity and
mortality of this condition, the exact molecular mechanisms that are involved in the
development and progression of the disease are still unclear. Evidence of this fact is that
valve replacement, with either mechanical prosthetic or bioprosthetic valves, is the only
viable treatment for the disease. On average, 50,000 aortic valve replacements every year
occur both in Europe and in the United States. However, this involves open heart surgery
with its attendant risks and high costs for health organizations that are estimated to be
around 1 billion US dollars per year in the United States alone. Currently there is not
proven pharmacological treatment that will stop or reverse the morphological changes
seen in calcific aortic disease.
In vivo, the aortic valve is constantly exposed to a variety of humeral and
hemodynamic factors, and thus, a major limiting factor in the understanding of the
disease is the lack of well defined experimental models that resemble native valve
environment in vitro.It is well established that one of the major causes of this
pathological condition is the exposure of valve tissue to non-physiological hemodynamic
102

stresses. The focus of this study was on the quantification of the effects of elevated
pressure on valve calcification. At this point, it must be noted that other sources of
mechanical load (stretch, shear) are present in the native environment of the valve.
However, elucidation of the effects of elevated pressure does serve as an important clue
that hypertension might both mediate molecular alterations and promote a calcifying cell
phenotype in aortic valve.
Correlation studies between aortic valve calcification and hypertension suggest
that the calcification process may occur as a result to the abnormal environment
generated by elevated pressure. While development of calcific aortic valve disease
requires the coordination of many factors that include pro inflammatory stimuli, valvular
ECM remodeling, and pro-apoptotic mechanisms, a critical step in the calcification
process is the osteoblast transformation of valvular interstitial cells (VICs). The question
of the potential interrelation of hypertension with valve calcification and its functional
role concerning regulation osteogenic differentiation of valvular interstitial cells has not
been established.
To elucidate the potential regulatory functions of hypertension in valve
calcification, we evaluated the effects of elevated pressure on osteogenic differentiation
of valve interstitial cells in vitro. In addition, we investigated the potential molecular
mechanisms mediating the differentiation process. In the first part of this work (Chapter
3), we characterized the phenotypic changes of valve interstitial exposed to physiological
and pathological levels of cyclic pressure. Our results indicate the potential capacity of
elevated pressure to induce valve calcification by regulation of osteogenesis-associated
genes in valvular interstitial cells.
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Based on the observations presented in Chapter 2, where pressure induced new
gene expression of three typical osteoblast specific genes, we identified in the following
section of the study, the global gene expression patterns and signaling pathways activated
in aortic heart valve exposed to hypertensive pressure. We showed that elevated cyclic
pressure is a potent regulator of gene expression levels in valve tissue, thus elevated
cyclic pressure was able to activate several molecular mechanisms that relate to ECM
tissue remodeling: inflammation, cell death, and osteogenic differentiation. Changes in
gene expression levels related to the inflammatory response, ECM remodeling and cell
proliferation occurring in elevated pressure conditions are expected to result from the
activation of VICs as a response to increased mechanical loading. Our results suggest that
the valve remodeling mechanisms activated by elevated pressure lead to the development
of calcific aortic valve disease.
We concluded that hypertensive pressure plays an important role in
transcriptional activation of several mechanisms, including local production of proteins,
such as osteopontin, runt related factor 2, alkaline phosphatase, which mediate tissue
calcification; expression pro inflammatory cytokines, activation of oxidative stress, and
apoptosis signaling pathways; along with changes in tissue matrix, including the up
regulation of matrix metalloproteinases and TP53 activity. In addition, valve interstitial
cells undergo phenotypic transformation into osteoblasts that may be regulated by the
BMP-7 signaling pathway.
Together, our data identifies new considerable factors that relate elevated pressure
to the initiation of calcific aortic valve disease, but further work is required to identify
additional target genes in the calcification process that may be inhibited to form the basis
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of new effective pharmacological treatments. A further approach might be to target
intermediate effectors of the Ang II signaling pathway to understand the roles of this
system in aortic heart valve.
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APPENDIX A
PORCINE GENECHIP SPECIFICATIONS
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Porcine GeneChip Genome Array Specifications
Number of probe sets

23,937

Number of transcripts,

23,256

Total # of probe sets including species
specific controls

23,973

Number of arrays in set One

One

Array format

100

Feature size

11 μm

Oligonucleotide probe length

25-mer

Probe pairs/sequence

11

Hybridization controls:

bioB, bioC, bioD from E. coli and cre from
P1 Bacteriophage

Poly-A controls:

dap, lys, phe, thr, trp from B. subtilis

Housekeeping/Control genes:

Porcine genes from Test3 Array: Alpha
Actin, Angiotesinbinding protein, CTLA4,
Erythropoietin
receptor,
GAPDH,
inflammatory response protein 6, and
Leptin. Additionally, there are newly
selected control probe sets for Beta Actin
(ACTB),
Glyceraldehyde-3-phosphate
dehydrogenase (GAPD, G3PD, GAPDH),
Eukaryotic elongation factor1 alpha1
(EEF1A1).

Detection sensitivity

1:100,000*

* As measured by detection in comparative analysis between a complex target containing
spiked control transcriptions and a complex target with no spikes.
The sequence information for this array was selected from public data sources including
Porcine UniGene Build 28, and GenBank® mRNAs (August 2004)
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APPENDIX B
MICROARRAY INTERNAL CONTROLS
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Origin of Control

Control Gene Name

Type of Controls

b.subtilis

lis
Phe
thr
dap

Poly-A-tailed sense RNAs used as
controls for the labeling and
hybridization process.
Used to estimate assay sensitivity

E.coli
P1 Bacteriphage
Synthetic

bioB
bioC
bioD
Cre
B2 Oligo
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Antisense biotinylated cRNAs used
as hybridization controls
Grid aligment

APPENDIX C
HYBRIDIZATION PERFORMANCE OF MICROARRAYS
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APPENDIX D
GENES DIFFERENTIALLY EXPRESSED IN PORCINE VALVE TISSUE IN
RESPONSE TO ELEVATED CYCLIC PRESSURE
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*(+), increased expression. (-), decreased expression.
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*(+), increased expression. (-), decreased expression.
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*(+), increased expression. (-),decreased expression
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APPENDIX E
HIERARCHICAL CLUSTERING OF MICROARRAY HYBRIDIZATIONS
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*Cluster analysis of hybridizations and genes performed using GeneTraffic UNO
(Iobion Informatics LLC).
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